tazarotene has been researched along with Psoriasis in 152 studies
tazarotene: a topical acetylenic retinoid; a topical kerytolytic
tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and safety of FCL plus topical tazarotene versus tazarotene monotherapy in the treatment of nail psoriasis." | 9.51 | Efficacy of combined fractional carbon dioxide laser and topical tazarotene in nail psoriasis treatment: A randomized intrapatient left-to-right study. ( Essa Abd Elazim, N; Mahmoud Abdelsalam, A; Mohamed Awad, S, 2022) |
| "The topical corticosteroid halobetasol propionate (HP) and the retinoid tazarotene (TAZ) are effective in psoriasis treatment." | 9.41 | Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. ( Han, G; Harris, S; Jacobson, A; Lebwohl, MG; Lin, T; Papp, K; Pariser, DM; Stein Gold, L, 2021) |
| "Long-term use of corticosteroids or local use of tazarotene (TAZ) alone for the treatment of psoriasis cause safety issues and low compliance rates." | 9.34 | Fixed combination of tazarotene and betamethasone dipropionate for treatment of psoriasis vulgaris: The result of a phase 3, multicenter, randomized controlled trial. ( Chen, H; Gu, J; Li, M; Liu, X; Lou, D; Sun, J; Sun, Q; Wen, H; Yang, H; Zhang, J, 2020) |
| "The efficacy of topical tazarotene has not previously been compared with the conventional topical treatment of crude coal tar (CCT) in stable plaque psoriasis." | 9.14 | Topical tazarotene vs. coal tar in stable plaque psoriasis. ( De, D; Dogra, S; Kaur, I; Kumar, B; Kumar, U, 2010) |
| "We present the results of a multicentre, not controlled, clinical study on the tolerability and efficacy of tazarotene gel, used as short contact therapy (SCT), in psoriasis vulgaris." | 9.12 | Short contact therapy with tazarotene in psoriasis vulgaris. ( Caputo, R; Chimenti, S; Pacifico, A; Peris, K; Soda, R; Veraldi, S, 2006) |
| "To investigate the mechanism of tazarotene against active psoriasis vulgaris." | 9.12 | [Inhibition of promyelocytic leukemia gene by tazarotene in hyperproliferative epidermis of psoriasis]. ( Liu, P; Peng, ZH; Tan, SS; Wang, QY; Yan, HL, 2006) |
| "Tazarotene and calcipotriol are both effective in the treatment of psoriasis." | 9.11 | Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis. ( Chen, YH; Ger, LP; Hsu, NJ; Tzung, TY; Wu, JC, 2005) |
| "To compare the therapeutic response to tacalcitol plus PUVA, tazarotene plus PUVA and PUVA monotherapy in patients with chronic plaque-type psoriasis." | 9.10 | A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. ( Hönigsmann, H; Seeber, A; Tanew, A; Tzaneva, S, 2002) |
| "Tazarotene in a gel formulation is widely used in the treatment of psoriasis." | 9.10 | Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. ( Gibson, JR; Koo, JY; Krueger, GG; Lebwohl, MG; Lew-Kaya, DA; Lowe, NJ; Menter, MA; Sefton, J; Walker, PS; Weinstein, GD, 2003) |
| "Both calcipotriene and tazarotene have been shown to be effective in the treatment of psoriasis." | 9.10 | Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. ( Bowman, PH; Koo, JY; Maloney, JE, 2002) |
| "The addition of tazarotene to narrow-band UVB phototherapy promotes more effective, faster clearing of psoriasis compared with UVB (311 nm) monotherapy." | 9.09 | Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. ( Behrens, S; Grundmann-Kollmann, M; Kerscher, M; Peter, RU; Schiener, R, 2000) |
| "Both tazarotene (a retinoid prodrug) and calcipotriene (a synthetic analog of vitamin D3) are effective in the treatment of plaque psoriasis, but no reports in the literature directly compare the efficacy and tolerability of these 2 drugs." | 9.09 | A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. ( Guenther, LC; Pariser, DM; Poulin, YP, 2000) |
| "Ten patients suffering from widespread symmetrical psoriasis were treated for at least 4 weeks with topical calcipotriol and tazarotene in a half-side distribution." | 9.09 | Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis. ( Behrens-Williams, SC; Kaskel, P; Kerscher, M; Peter, RU; Pillekamp, H; Schiener, R, 2000) |
| "The results of a multicenter, open-label observation study evaluating the use of tazarotene in 1393 patients being treated for plaque psoriasis have been reported recently." | 9.09 | An observation study evaluating the efficacy of tazarotene plus corticosteroid in treating plaque psoriasis in patients switched from treatment with calcipotriene +/- corticosteroid. ( Tanghetti, EA, 2000) |
| "Overall results from a multicenter study involving more than 1000 patients with plaque psoriasis treated with tazarotene 0." | 9.09 | Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment. ( Coynik, D, 2000) |
| "A large-scale observation study has been performed to evaluate how tazarotene is used to treat plaque psoriasis in everyday clinical practice and to elucidate whether the efficacy and tolerability of tazarotene treatment can be optimized through the adjunctive use of an emollient and/or a topical corticosteroid." | 9.09 | An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid. ( Tanghetti, EA, 2000) |
| "Our purpose was to evaluate a new topical retinoid, tazarotene, in the treatment of stable plaque psoriasis during treatment and posttreatment periods." | 9.08 | Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. ( Chandraratna, RA; Duvic, M; Friedman, DJ; Gibson, JR; Jegasothy, BV; Jorizzo, JL; Krueger, GG; Lew-Kaya, DA; Lowe, NJ; Lue, JC; Sefton, J; Shmunes, E; Tschen, EH; Weinstein, GD, 1997) |
| "All tazarotene combinations (including tazarotene plus placebo) were highly effective in rapidly reducing the severity of psoriasis." | 9.08 | Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. ( Breneman, DL; Gibson, JR; Goffe, BS; Grossman, JR; Lebwohl, MG; Lew-Kaya, DA; Ling, MR; Lue, JC; Milbauer, J; Pincus, SH; Sefton, J; Sibbald, RG; Swinyer, LJ; Weinstein, GD, 1998) |
| " The first topical receptor-selective retinoid to be approved for the treatment of plaque psoriasis is tazarotene." | 8.83 | Receptor-selective retinoids for psoriasis: focus on tazarotene. ( Korting, HC; Roeder, A; Schäfer-Korting, M; Schaller, M; Weindl, G, 2006) |
| "Tazarotene (Tazorac) is a topical retinoid indicated for the treatment of plaque psoriasis." | 8.82 | Topical tazarotene: a review of its use in the treatment of plaque psoriasis. ( Dando, TM; Wellington, K, 2005) |
| "Tazarotene (AGN 190168) is a new acetylenic retinoid which is effective for the topical treatment of patients with stable plaque psoriasis and mild to moderate acne vulgaris." | 8.80 | Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. ( Matsumoto, RM; Tang-Liu, DD; Usansky, JI, 1999) |
| "The recent availability of tazarotene, the first receptor-selective retinoid, provides a much-needed addition to the therapeutic armamentarium for mild-to-moderate plaque psoriasis." | 8.80 | The role of tazarotene in the treatment of psoriasis. ( Marks, R, 1999) |
| "In the hope of increasing efficacy and improving safety, several combination regimens involving tazarotene gel have been explored for the treatment of plaque psoriasis." | 8.80 | Tazarotene combination treatments in psoriasis. ( Guenther, L, 2000) |
| "Tazarotene belongs to a novel, nonisomerizable class of retinoic acid receptor (RAR)-specific retinoids, the acetylenic retinoids, and is the first topical retinoid developed for the treatment of psoriasis." | 8.79 | Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. ( Chandraratna, RA, 1997) |
| "Tazarotene is the first of a new generation of acetylenic retinoids developed for the topical treatment of mild-to-moderate plaque psoriasis." | 8.79 | Tazarotene gel: efficacy and safety in plaque psoriasis. ( Weinstein, GD, 1997) |
| "This was an open-label investigator-initiated trial involving 21 patients with moderate-to-severe palmoplantar plaque-type psoriasis who underwent treatment with halobetasol propionate 0." | 8.31 | An Investigator-Initiated Trial of a Polymeric Emulsion of Halobetasol Propionate and Tazarotene in the Treatment of Palmoplantar Psoriasis. ( Babalola, F; Campbell, C; Gottlieb, A; Mitchell, K; Vargas, J; Yousif, J, 2023) |
| "Recently, clinical data on 8 weeks’ once-daily treatment of localized moderate-to-severe psoriasis with a novel fixed combination halobetasol propionate 0." | 7.91 | Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis ( Blauvelt, A; Green, LJ; Lebwohl, MG; Lin, T; Martin, G; Pillai, R; Yamauchi, PS, 2019) |
| "Tazarotene is a topically-applied, receptor-selective retinoid that has been shown to modulate several major pathogenic factors of psoriasis." | 7.80 | Periungual pyogenic granulomas due to topical tazarotene for nail psoriasis. ( Patrizi, A; Piraccini, BM; Venturi, M, 2014) |
| "In the treatment of plaque psoriasis with corticosteroids, long-term efficacy and safety are often compromised by tachyphylaxis, steroid rebound, and adverse effects." | 7.79 | Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. ( Lebwohl, M, 2000) |
| "Our study shows the therapeutic potential of tazarotene ointment in nail psoriasis." | 7.78 | Nail psoriasis: treatment with tazarotene 0.1% hydrophilic ointment. ( Collgros, H; Expósito-Serrano, V; Fischer-Levancini, C; Llambí, F; Sánchez-Regaña, M; Umbert-Millet, P, 2012) |
| "Tazarotene is the first receptor-selective retinoid indicated for the topical treatment of plaque psoriasis." | 7.70 | In vitro compatibility of tazarotene with other topical treatments of psoriasis. ( Hecker, D; Lebwohl, M; Worsley, J; Yueh, G, 2000) |
| "Psoriasis is a complex and chronic disease with treatment needs that may change over time, influencing patient treatment goals and expectations of efficacy." | 7.01 | Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion. ( Armstrong, A; Del Rosso, J; Han, G; Jacobson, A; Lewitt, GM, 2023) |
| "Tazarotene has also been shown to be effective in psoriasis, with efficacy maintained several weeks posttreatment." | 6.90 | Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy ( , 2019) |
| " Safety and treatment emergent adverse events (TEAEs) were evaluated throughout." | 6.90 | Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials ( Israel, R; Lebwohl, MG; Lin, T; Stein Gold, L; Sugarman, JL, 2019) |
| " Safety and treatment-emergent adverse events were evaluated throughout." | 6.87 | Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. ( Gold, LS; Israel, R; Lebwohl, MG; Lin, T; Martin, G; Pariser, DM; Pillai, R; Ramakrishna, T; Sugarman, JL, 2018) |
| "Tazarotene has also been shown to be effective in psoriasis, with efficacy maintained several weeks posttreatment." | 6.87 | Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy. ( Green, LJ; Lin, T; Pariser, DM; Pillai, R; Stein Gold, L; Sugarman, JL, 2018) |
| "Psoriasis is a chronic condition often managed with topical therapy." | 6.87 | Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination. ( Kang, R; Kircik, LH; Lin, T; Pariser, D; Pillai, R; Stein Gold, L; Sugarman, JL, 2018) |
| " Safety and treatment emergent adverse events (TEAEs) were evaluated throughout." | 6.84 | A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis. ( Alexander, BJ; Gold, LS; Lebwohl, MG; Pariser, DM; Pillai, R; Sugarman, JL, 2017) |
| "The tazarotene treatment resulted in a significantly greater reduction in onycholysis in occluded nails (P < or = ." | 6.70 | Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. ( Scher, RK; Stiller, M; Zhu, YI, 2001) |
| " Treatment-related adverse effects were generally limited to mild or moderate local irritation and were less frequent with the treatment regimen administered once daily." | 6.69 | The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. ( Chandraratna, RA; Drake, LA; Elias, PM; Guzzo, C; Krueger, GG; Lew-Kaya, DA; Lowe, NJ; Lue, JC; Sefton, J; Weinstein, GD, 1998) |
| "Both tazarotene gels were as effective as fluocinonide in reducing plaque elevation after 1 week of treatment, and tazarotene 0." | 6.69 | Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. ( Ast, E; Callen, JP; Chandraratna, RA; Cullen, SI; Gibson, JR; Hong, SR; Kulp-Shorten, CL; Lebwohl, M; Lowe, NJ; Lue, JC; Phillips, TJ; Quell, JM; Rosen, T; Sefton, J; Wolf, DI, 1998) |
| "Tazarotene was administered once daily in the evening, and mometasone furoate was administered once daily in the morning, for 12 weeks or until clearance if this occurred first." | 6.69 | Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. ( Poulin, YP, 1999) |
| "Tazarotene is a new topical retinoid which has proven to be efficacious in the treatment of mild-to-moderate plaque psoriasis." | 6.68 | Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis. ( Weinstein, GD, 1996) |
| "Psoriasis is a prevalent cutaneous condition with severe physical and psychological manifestations." | 6.58 | Pharmacokinetics of tazarotene and acitretin in psoriasis. ( Curry, ZA; Feldman, SR; Heath, MS; Sahni, DR, 2018) |
| " The most common side effect is mild-to-moderate local irritation, which limited its role as a single agent for psoriasis." | 6.58 | Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy ( Lebwohl, M; Stein Gold, L; Tanghetti, E, 2018) |
| "Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population." | 6.43 | Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus. ( Saini, R; Tutrone, WD; Weinberg, JM, 2005) |
| "Tazarotene is a pro-drug of tazarotenic acid, a receptor-selective retinoid, which has shown efficacy in the treatment of these disorders." | 6.41 | Topical tazarotene therapy for psoriasis, acne vulgaris, and photoaging. ( Guenther, LC, 2002) |
| "Tazarotene is a retinoic acid receptor-specific retinoid with demonstrated efficacy in the topical treatment of psoriasis." | 6.40 | Molecular mechanisms of tazarotene action in psoriasis. ( Asano, AT; Chandraratna, RA; Duvic, M; Nagpal, S, 1997) |
| "Tazarotene is a novel acetylenic retinoid undergoing clinical trials for the topical treatment of mild-to-moderate plaque psoriasis." | 6.40 | Clinical safety of tazarotene in the treatment of plaque psoriasis. ( Marks, R, 1997) |
| "Psoriasis is associated with upregulation or downregulation of several of these markers." | 6.40 | The pathogenesis of psoriasis and the mechanism of action of tazarotene. ( Asano, AT; Duvic, M; Hager, C; Mays, S, 1998) |
| "Psoriasis is a complex inflammatory disease, which can be triggered by the interplay among keratinocytes, various immune cells, and even dermal vascular endothelial cells." | 5.91 | Supplement Individual Article: A Reappraisal of Fixed-Combination Halobetasol Propionate and Tazarotene for the Treatment of Psoriasis: Biological Underpinnings, Therapeutic Mechanisms, and Economic Considerations. ( Issa, N; Kircik, L, 2023) |
| "To evaluate the efficacy and safety of FCL plus topical tazarotene versus tazarotene monotherapy in the treatment of nail psoriasis." | 5.51 | Efficacy of combined fractional carbon dioxide laser and topical tazarotene in nail psoriasis treatment: A randomized intrapatient left-to-right study. ( Essa Abd Elazim, N; Mahmoud Abdelsalam, A; Mohamed Awad, S, 2022) |
| "The topical corticosteroid halobetasol propionate (HP) and the retinoid tazarotene (TAZ) are effective in psoriasis treatment." | 5.41 | Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. ( Han, G; Harris, S; Jacobson, A; Lebwohl, MG; Lin, T; Papp, K; Pariser, DM; Stein Gold, L, 2021) |
| "Long-term use of corticosteroids or local use of tazarotene (TAZ) alone for the treatment of psoriasis cause safety issues and low compliance rates." | 5.34 | Fixed combination of tazarotene and betamethasone dipropionate for treatment of psoriasis vulgaris: The result of a phase 3, multicenter, randomized controlled trial. ( Chen, H; Gu, J; Li, M; Liu, X; Lou, D; Sun, J; Sun, Q; Wen, H; Yang, H; Zhang, J, 2020) |
| "Tazarotene (TAZ) is a topical synthetic retinoid used in psoriasis treatment, however, it is extremely lipophilic and exhibits skin irritation." | 5.30 | Novel antipsoriatic fluidized spanlastic nanovesicles: In vitro physicochemical characterization, ex vivo cutaneous retention and exploratory clinical therapeutic efficacy. ( El-Gogary, RI; Elmowafy, E; Nasr, M; Ragai, MH, 2019) |
| "The efficacy of topical tazarotene has not previously been compared with the conventional topical treatment of crude coal tar (CCT) in stable plaque psoriasis." | 5.14 | Topical tazarotene vs. coal tar in stable plaque psoriasis. ( De, D; Dogra, S; Kaur, I; Kumar, B; Kumar, U, 2010) |
| "We present the results of a multicentre, not controlled, clinical study on the tolerability and efficacy of tazarotene gel, used as short contact therapy (SCT), in psoriasis vulgaris." | 5.12 | Short contact therapy with tazarotene in psoriasis vulgaris. ( Caputo, R; Chimenti, S; Pacifico, A; Peris, K; Soda, R; Veraldi, S, 2006) |
| "To investigate the mechanism of tazarotene against active psoriasis vulgaris." | 5.12 | [Inhibition of promyelocytic leukemia gene by tazarotene in hyperproliferative epidermis of psoriasis]. ( Liu, P; Peng, ZH; Tan, SS; Wang, QY; Yan, HL, 2006) |
| "Tazarotene and calcipotriol are both effective in the treatment of psoriasis." | 5.11 | Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis. ( Chen, YH; Ger, LP; Hsu, NJ; Tzung, TY; Wu, JC, 2005) |
| "To compare the therapeutic response to tacalcitol plus PUVA, tazarotene plus PUVA and PUVA monotherapy in patients with chronic plaque-type psoriasis." | 5.10 | A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. ( Hönigsmann, H; Seeber, A; Tanew, A; Tzaneva, S, 2002) |
| "Tazarotene in a gel formulation is widely used in the treatment of psoriasis." | 5.10 | Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. ( Gibson, JR; Koo, JY; Krueger, GG; Lebwohl, MG; Lew-Kaya, DA; Lowe, NJ; Menter, MA; Sefton, J; Walker, PS; Weinstein, GD, 2003) |
| "Retinoids like tazarotene are approved for the treatment of chronic plaque psoriasis." | 5.10 | Instrumental evaluation of retinoid-induced skin irritation. ( Altmeyer, P; Hoffmann, M; Stücker, M, 2002) |
| "Both calcipotriene and tazarotene have been shown to be effective in the treatment of psoriasis." | 5.10 | Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. ( Bowman, PH; Koo, JY; Maloney, JE, 2002) |
| "Tazarotene in combination with phototherapy is being used clinically for the treatment of plaque psoriasis." | 5.09 | Interactions between tazarotene and ultraviolet light. ( Hecker, D; Kuroda, K; Lebwohl, M; Worsley, J; Yueh, G, 1999) |
| "The addition of tazarotene to narrow-band UVB phototherapy promotes more effective, faster clearing of psoriasis compared with UVB (311 nm) monotherapy." | 5.09 | Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. ( Behrens, S; Grundmann-Kollmann, M; Kerscher, M; Peter, RU; Schiener, R, 2000) |
| "Both tazarotene (a retinoid prodrug) and calcipotriene (a synthetic analog of vitamin D3) are effective in the treatment of plaque psoriasis, but no reports in the literature directly compare the efficacy and tolerability of these 2 drugs." | 5.09 | A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. ( Guenther, LC; Pariser, DM; Poulin, YP, 2000) |
| "Ten patients suffering from widespread symmetrical psoriasis were treated for at least 4 weeks with topical calcipotriol and tazarotene in a half-side distribution." | 5.09 | Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis. ( Behrens-Williams, SC; Kaskel, P; Kerscher, M; Peter, RU; Pillekamp, H; Schiener, R, 2000) |
| "The results of a multicenter, open-label observation study evaluating the use of tazarotene in 1393 patients being treated for plaque psoriasis have been reported recently." | 5.09 | An observation study evaluating the efficacy of tazarotene plus corticosteroid in treating plaque psoriasis in patients switched from treatment with calcipotriene +/- corticosteroid. ( Tanghetti, EA, 2000) |
| "Overall results from a multicenter study involving more than 1000 patients with plaque psoriasis treated with tazarotene 0." | 5.09 | Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment. ( Coynik, D, 2000) |
| "A large-scale observation study has been performed to evaluate how tazarotene is used to treat plaque psoriasis in everyday clinical practice and to elucidate whether the efficacy and tolerability of tazarotene treatment can be optimized through the adjunctive use of an emollient and/or a topical corticosteroid." | 5.09 | An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid. ( Tanghetti, EA, 2000) |
| "Our purpose was to evaluate a new topical retinoid, tazarotene, in the treatment of stable plaque psoriasis during treatment and posttreatment periods." | 5.08 | Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. ( Chandraratna, RA; Duvic, M; Friedman, DJ; Gibson, JR; Jegasothy, BV; Jorizzo, JL; Krueger, GG; Lew-Kaya, DA; Lowe, NJ; Lue, JC; Sefton, J; Shmunes, E; Tschen, EH; Weinstein, GD, 1997) |
| "All tazarotene combinations (including tazarotene plus placebo) were highly effective in rapidly reducing the severity of psoriasis." | 5.08 | Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. ( Breneman, DL; Gibson, JR; Goffe, BS; Grossman, JR; Lebwohl, MG; Lew-Kaya, DA; Ling, MR; Lue, JC; Milbauer, J; Pincus, SH; Sefton, J; Sibbald, RG; Swinyer, LJ; Weinstein, GD, 1998) |
| "To review a decade of experience using tazarotene as a monotherapy or as combination therapy for approved and other indications: acne, psoriasis, photoaging, basal cell carcinomas and various keratinization disorders." | 4.85 | Efficacy and safety of topical tazarotene: a review. ( Cox, K; Duvic, M; Talpur, R, 2009) |
| " The first topical receptor-selective retinoid to be approved for the treatment of plaque psoriasis is tazarotene." | 4.83 | Receptor-selective retinoids for psoriasis: focus on tazarotene. ( Korting, HC; Roeder, A; Schäfer-Korting, M; Schaller, M; Weindl, G, 2006) |
| "Tazarotene is a receptor-selective retinoid, which is efficacious in the treatment of patients with psoriasis, acne vulgaris, and photoaging." | 4.82 | Optimizing treatment with topical tazarotene. ( Guenther, LC, 2003) |
| "Tazarotene (Tazorac) is a topical retinoid indicated for the treatment of plaque psoriasis." | 4.82 | Topical tazarotene: a review of its use in the treatment of plaque psoriasis. ( Dando, TM; Wellington, K, 2005) |
| "Tazarotene is the first topical retinoid demonstrated to be both effective and tolerable in the treatment of psoriasis." | 4.80 | Clinical efficacy and safety of tazarotene: optimizing clinical results. ( Lebwohl, M, 1998) |
| "Tazarotene (AGN 190168) is a new acetylenic retinoid which is effective for the topical treatment of patients with stable plaque psoriasis and mild to moderate acne vulgaris." | 4.80 | Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. ( Matsumoto, RM; Tang-Liu, DD; Usansky, JI, 1999) |
| "The recent availability of tazarotene, the first receptor-selective retinoid, provides a much-needed addition to the therapeutic armamentarium for mild-to-moderate plaque psoriasis." | 4.80 | The role of tazarotene in the treatment of psoriasis. ( Marks, R, 1999) |
| "In the hope of increasing efficacy and improving safety, several combination regimens involving tazarotene gel have been explored for the treatment of plaque psoriasis." | 4.80 | Tazarotene combination treatments in psoriasis. ( Guenther, L, 2000) |
| "Tazarotene belongs to a novel, nonisomerizable class of retinoic acid receptor (RAR)-specific retinoids, the acetylenic retinoids, and is the first topical retinoid developed for the treatment of psoriasis." | 4.79 | Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. ( Chandraratna, RA, 1997) |
| "Tazarotene is the first of a new generation of acetylenic retinoids developed for the topical treatment of mild-to-moderate plaque psoriasis." | 4.79 | Tazarotene gel: efficacy and safety in plaque psoriasis. ( Weinstein, GD, 1997) |
| "This was an open-label investigator-initiated trial involving 21 patients with moderate-to-severe palmoplantar plaque-type psoriasis who underwent treatment with halobetasol propionate 0." | 4.31 | An Investigator-Initiated Trial of a Polymeric Emulsion of Halobetasol Propionate and Tazarotene in the Treatment of Palmoplantar Psoriasis. ( Babalola, F; Campbell, C; Gottlieb, A; Mitchell, K; Vargas, J; Yousif, J, 2023) |
| "Recently, clinical data on 8 weeks’ once-daily treatment of localized moderate-to-severe psoriasis with a novel fixed combination halobetasol propionate 0." | 3.91 | Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis ( Blauvelt, A; Green, LJ; Lebwohl, MG; Lin, T; Martin, G; Pillai, R; Yamauchi, PS, 2019) |
| "Tazarotene is a topically-applied, receptor-selective retinoid that has been shown to modulate several major pathogenic factors of psoriasis." | 3.80 | Periungual pyogenic granulomas due to topical tazarotene for nail psoriasis. ( Patrizi, A; Piraccini, BM; Venturi, M, 2014) |
| "The use of a topical corticosteroid in combination with tazarotene has theoretic appeal because each drug has a different mechanism of action, and it is therefore likely that combination therapy will offer additive or synergistic effects." | 3.79 | Tazarotene in combination with topical corticosteroids. ( Lebwohl, M; Poulin, Y, 1998) |
| "In the treatment of plaque psoriasis with corticosteroids, long-term efficacy and safety are often compromised by tachyphylaxis, steroid rebound, and adverse effects." | 3.79 | Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. ( Lebwohl, M, 2000) |
| "Our study shows the therapeutic potential of tazarotene ointment in nail psoriasis." | 3.78 | Nail psoriasis: treatment with tazarotene 0.1% hydrophilic ointment. ( Collgros, H; Expósito-Serrano, V; Fischer-Levancini, C; Llambí, F; Sánchez-Regaña, M; Umbert-Millet, P, 2012) |
| "Oral acitretin is currently indicated for the treatment of severe psoriasis in adults, but its use is limited by systemic side effects and teratogenicity." | 3.74 | Effects of topically applied acitretin in reconstructed human epidermis and the rhino mouse. ( Chern, WH; Hofland, HE; Houlden, RJ; Hsia, E; Johnston, MJ, 2008) |
| "Tazarotene topical gel (Tazorac) is a vitamin A derivative and the first topical retinoid to demonstrate therapeutic success in treating plaque-type psoriasis." | 3.70 | Obtaining the optimal treatment outcome with tazarotene. ( McClelland, PB, 1998) |
| "Based on currently available data, tazarotene can be used for the treatment of chronic, stable, plaque-type psoriasis, on the trunk or limbs covering up to 20% of the body surface area." | 3.70 | Optimising the use of tazarotene in clinical practice: consensus statement from the European advisory panel for tazarotene (Zorac TM). ( Barker, JN; Finzi, AF; Gollnick, HP; Jansen, C; Marks, R; Revuz, J; Saurat, J, 1999) |
| "Tazarotene is the first receptor-selective retinoid indicated for the topical treatment of plaque psoriasis." | 3.70 | In vitro compatibility of tazarotene with other topical treatments of psoriasis. ( Hecker, D; Lebwohl, M; Worsley, J; Yueh, G, 2000) |
| " Using a subtraction hybridization approach, we have identified a cDNA sequence, Tazarotene Induced Gene 1 (TIG1), which is highly upregulated in skin raft cultures by an RARbeta/gamma -selective retinoid AGN 190168 (tazarotene/ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)-ethynyl]nicotinate), which is effective in the treatment of psoriasis." | 3.69 | Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin. ( Asano, AT; Chandraratna, RA; Duvic, M; Johnson, AT; Nagpal, S; Patel, S, 1996) |
| " Tazarotene (AGN 190168), a retinoic acid receptor (RAR)-specific retinoid, is effective in the treatment of psoriasis, a hyperproliferative and inflammatory skin disease." | 3.69 | Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acid receptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis. ( Asano, AT; Chandraratna, RA; Duvic, M; Friant, S; Krasinski, G; Malhotra, M; Nagpal, S; Patel, S; Shafer, J; Teng, M; Thacher, SM, 1996) |
| "Initial clinical investigations on tazarotene, a new acetylenic retinoid, have suggested potential usefulness in the treatment of mild-to-moderate plaque psoriasis." | 3.69 | Early clinical development of tazarotene. ( Marks, R, 1996) |
| "Psoriasis is a complex and chronic disease with treatment needs that may change over time, influencing patient treatment goals and expectations of efficacy." | 3.01 | Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion. ( Armstrong, A; Del Rosso, J; Han, G; Jacobson, A; Lewitt, GM, 2023) |
| "Tazarotene has also been shown to be effective in psoriasis, with efficacy maintained several weeks posttreatment." | 2.90 | Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy ( , 2019) |
| " Safety and treatment emergent adverse events (TEAEs) were evaluated throughout." | 2.90 | Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials ( Israel, R; Lebwohl, MG; Lin, T; Stein Gold, L; Sugarman, JL, 2019) |
| " Safety and treatment-emergent adverse events were evaluated throughout." | 2.87 | Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. ( Gold, LS; Israel, R; Lebwohl, MG; Lin, T; Martin, G; Pariser, DM; Pillai, R; Ramakrishna, T; Sugarman, JL, 2018) |
| "Tazarotene has also been shown to be effective in psoriasis, with efficacy maintained several weeks posttreatment." | 2.87 | Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy. ( Green, LJ; Lin, T; Pariser, DM; Pillai, R; Stein Gold, L; Sugarman, JL, 2018) |
| "Psoriasis is a chronic condition often managed with topical therapy." | 2.87 | Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination. ( Kang, R; Kircik, LH; Lin, T; Pariser, D; Pillai, R; Stein Gold, L; Sugarman, JL, 2018) |
| " Safety and treatment emergent adverse events (TEAEs) were evaluated throughout." | 2.84 | A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis. ( Alexander, BJ; Gold, LS; Lebwohl, MG; Pariser, DM; Pillai, R; Sugarman, JL, 2017) |
| "Nail psoriasis is difficult to treat." | 2.78 | Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: a single-blind, intrapatient left-to-right controlled study. ( Chiang, YY; Chou, CL; Huang, YC, 2013) |
| "The tazarotene treatment resulted in a significantly greater reduction in onycholysis in occluded nails (P < or = ." | 2.70 | Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. ( Scher, RK; Stiller, M; Zhu, YI, 2001) |
| " Treatment-related adverse effects were generally limited to mild or moderate local irritation and were less frequent with the treatment regimen administered once daily." | 2.69 | The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. ( Chandraratna, RA; Drake, LA; Elias, PM; Guzzo, C; Krueger, GG; Lew-Kaya, DA; Lowe, NJ; Lue, JC; Sefton, J; Weinstein, GD, 1998) |
| "Both tazarotene gels were as effective as fluocinonide in reducing plaque elevation after 1 week of treatment, and tazarotene 0." | 2.69 | Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. ( Ast, E; Callen, JP; Chandraratna, RA; Cullen, SI; Gibson, JR; Hong, SR; Kulp-Shorten, CL; Lebwohl, M; Lowe, NJ; Lue, JC; Phillips, TJ; Quell, JM; Rosen, T; Sefton, J; Wolf, DI, 1998) |
| "Tazarotene was administered once daily in the evening, and mometasone furoate was administered once daily in the morning, for 12 weeks or until clearance if this occurred first." | 2.69 | Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. ( Poulin, YP, 1999) |
| "Phototherapy is often used in combination with other antipsoriatic treatments in an attempt to improve efficacy and reduce patients' cumulative exposure to radiation." | 2.69 | Optimizing therapy: tazarotene in combination with phototherapy. ( Lowe, NJ, 1999) |
| "Tazarotene is a new topical retinoid which has proven to be efficacious in the treatment of mild-to-moderate plaque psoriasis." | 2.68 | Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis. ( Weinstein, GD, 1996) |
| "Psoriasis is a prevalent cutaneous condition with severe physical and psychological manifestations." | 2.58 | Pharmacokinetics of tazarotene and acitretin in psoriasis. ( Curry, ZA; Feldman, SR; Heath, MS; Sahni, DR, 2018) |
| " The most common side effect is mild-to-moderate local irritation, which limited its role as a single agent for psoriasis." | 2.58 | Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy ( Lebwohl, M; Stein Gold, L; Tanghetti, E, 2018) |
| "Topical treatments for psoriasis include corticosteroids, vitamin D derivatives, tazarotene, anthralin, tacrolimus, pimecrolimus, and newer formulations of tar." | 2.53 | Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence. ( Stein Gold, LF, 2016) |
| "Psoriasis is a chronic inflammatory disease with a well-documented negative effect on the quality of life of affected patients." | 2.52 | Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments. ( Bangsgaard, N; Rørbye, C; Skov, L, 2015) |
| "Psoriasis is a chronic inflammatory disease causing important physical and psychological morbidity." | 2.45 | [Topical treatments for psoriasis in 2009]. ( Laffitte, E; Thielen, AM, 2009) |
| "Psoriasis is a chronic skin disease that affects millions of people throughout the world." | 2.44 | Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. ( Jiaravuthisan, MM; Muhn, CY; Murphy, F; Sasseville, D; Vender, RB, 2007) |
| "Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population." | 2.43 | Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus. ( Saini, R; Tutrone, WD; Weinberg, JM, 2005) |
| "Psoriasis is a common disease in children and adolescents." | 2.43 | Treatment of childhood psoriasis. ( Ceović, R; Husar, K; Kostović, K; Lipozencić, J; Murat-Susić, S; Pasić, A; Skerlev, M, 2006) |
| " Our purpose is to compare the rates of adverse events associated with different topical psoriasis treatments." | 2.42 | A systematic review of adverse effects associated with topical treatments for psoriasis. ( Bruner, CR; Feldman, SR; Fleischer, AB; Ventrapragada, M, 2003) |
| "Tazarotene is an alternative for vitamin D(3) treatment if this treatment fails." | 2.42 | Established treatments of psoriasis. ( van de Kerkhof, PC; Vissers, WH, 2004) |
| " Limited systemic exposure to the drug also ensures that any adverse effects are local effects rather than systemic effects." | 2.41 | Pharmacokinetics and safety of tazarotene. ( Menter, A, 2000) |
| "Psoriasis is a complex disorder that negatively impacts quality of life." | 2.41 | Advances in psoriasis treatment. ( Feldman, S, 2000) |
| "Tazarotene is a pro-drug of tazarotenic acid, a receptor-selective retinoid, which has shown efficacy in the treatment of these disorders." | 2.41 | Topical tazarotene therapy for psoriasis, acne vulgaris, and photoaging. ( Guenther, LC, 2002) |
| "Tazarotene is a retinoic acid receptor-specific retinoid with demonstrated efficacy in the topical treatment of psoriasis." | 2.40 | Molecular mechanisms of tazarotene action in psoriasis. ( Asano, AT; Chandraratna, RA; Duvic, M; Nagpal, S, 1997) |
| "Tazarotene is a novel acetylenic retinoid undergoing clinical trials for the topical treatment of mild-to-moderate plaque psoriasis." | 2.40 | Clinical safety of tazarotene in the treatment of plaque psoriasis. ( Marks, R, 1997) |
| "Psoriasis is associated with upregulation or downregulation of several of these markers." | 2.40 | The pathogenesis of psoriasis and the mechanism of action of tazarotene. ( Asano, AT; Duvic, M; Hager, C; Mays, S, 1998) |
| "The tazarotene-UVB treatment was well tolerated, and no phototoxicity was observed." | 2.40 | Tazarotene in combination with phototherapy. ( Koo, JY, 1998) |
| "Tazarotene is a retinoid with properties that are a result of this rational approach to drug discovery." | 2.40 | Current research and future developments in retinoids: oral and topical agents. ( Chandraratna, RA, 1998) |
| "Psoriasis is a common dermatosis, affecting from 1 to 3 percent of the population." | 2.40 | Topical psoriasis therapy. ( Federman, DG; Froelich, CW; Kirsner, RS, 1999) |
| "Psoriasis is a complex inflammatory disease, which can be triggered by the interplay among keratinocytes, various immune cells, and even dermal vascular endothelial cells." | 1.91 | Supplement Individual Article: A Reappraisal of Fixed-Combination Halobetasol Propionate and Tazarotene for the Treatment of Psoriasis: Biological Underpinnings, Therapeutic Mechanisms, and Economic Considerations. ( Issa, N; Kircik, L, 2023) |
| "Psoriasis is a chronic, multisystem, inflammatory disease that affects approximately 1% of children, with onset most common during adolescence." | 1.56 | Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. ( Armstrong, AW; Connor, C; Cordoro, KM; Davis, DMR; Elewski, BE; Elmets, CA; Farley Prater, EA; Gelfand, JM; Gordon, KB; Gottlieb, AB; Hariharan, V; Kaplan, DH; Kavanaugh, A; Kiselica, M; Kivelevitch, D; Korman, NJ; Kroshinsky, D; Lebwohl, M; Leonardi, CL; Lichten, J; Lim, HW; Mehta, NN; Menter, A; Paller, AS; Parra, SL; Pathy, AL; Rupani, RN; Siegel, M; Stoff, B; Strober, BE; Wong, EB; Wu, JJ, 2020) |
| "Psoriasis is a chronic autoinflammatory disorder characterized by patches of abnormal skin." | 1.56 | Tazarotene-loaded ( Aydın, A; Erol, İ; Orak, D; Özer, Ö; Sipahi, H; Üstündağ Okur, N, 2020) |
| "Psoriasis is a heterogeneous inflammatory disorder that targets the skin and joints." | 1.39 | Improving outcomes in patients with psoriasis. ( Tidman, MJ, 2013) |
| "Psoriasis is a chronic, immune-mediated inflammatory and refractory disease." | 1.39 | Köebner phenomenon induced by cupping therapy in a psoriasis patient. ( Hui, Y; Li, CR; Yu, RX, 2013) |
| "(1) Plaque psoriasis is the most common form of psoriasis in children." | 1.35 | Childhood psoriasis: often favorable outcome. ( , 2009) |
| "Psoriasis is a chronic inflammatory skin disease in which epidermal proliferation is closely associated with excessive microvascular expansion within the papillary dermis." | 1.31 | Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. ( Fleischmajer, R; Kuroda, K; Lebwohl, M; Sapadin, A; Shoji, T, 2001) |
| "Tazarotene (Tazorac) is a new vitamin A derivative and the first topical retinoid to demonstrate therapeutic success in treating plaque-type psoriasis." | 1.30 | New treatment options for psoriasis. ( McClelland, PB, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 46 (30.26) | 18.2507 |
| 2000's | 51 (33.55) | 29.6817 |
| 2010's | 33 (21.71) | 24.3611 |
| 2020's | 22 (14.47) | 2.80 |
| Authors | Studies |
|---|---|
| Essa Abd Elazim, N | 1 |
| Mahmoud Abdelsalam, A | 1 |
| Mohamed Awad, S | 1 |
| Ozyurekoglu, E | 1 |
| Kircik, L | 4 |
| Guenther, L | 2 |
| Metelitsa, A | 1 |
| Prajapati, VH | 1 |
| Bagel, J | 3 |
| Novak, K | 1 |
| Nelson, E | 1 |
| Issa, N | 1 |
| Yousif, J | 1 |
| Babalola, F | 1 |
| Campbell, C | 1 |
| Gottlieb, A | 1 |
| Vargas, J | 1 |
| Mitchell, K | 1 |
| Del Rosso, J | 2 |
| Han, G | 3 |
| Armstrong, A | 1 |
| Lewitt, GM | 1 |
| Jacobson, A | 9 |
| Bhatia, N | 2 |
| Lain, E | 1 |
| Tanghetti, EA | 5 |
| Stein Gold, L | 10 |
| Del Rosso, JQ | 1 |
| Lin, T | 13 |
| Angel, A | 1 |
| Pillai, R | 10 |
| Lebwohl, MG | 8 |
| Sugarman, JL | 7 |
| Israel, R | 4 |
| Menter, A | 3 |
| Cordoro, KM | 1 |
| Davis, DMR | 1 |
| Kroshinsky, D | 1 |
| Paller, AS | 1 |
| Armstrong, AW | 1 |
| Connor, C | 1 |
| Elewski, BE | 1 |
| Gelfand, JM | 1 |
| Gordon, KB | 1 |
| Gottlieb, AB | 1 |
| Kaplan, DH | 1 |
| Kavanaugh, A | 1 |
| Kiselica, M | 1 |
| Kivelevitch, D | 1 |
| Korman, NJ | 1 |
| Lebwohl, M | 13 |
| Leonardi, CL | 1 |
| Lichten, J | 1 |
| Lim, HW | 1 |
| Mehta, NN | 1 |
| Parra, SL | 1 |
| Pathy, AL | 1 |
| Farley Prater, EA | 1 |
| Rupani, RN | 1 |
| Siegel, M | 1 |
| Stoff, B | 1 |
| Strober, BE | 1 |
| Wong, EB | 1 |
| Wu, JJ | 3 |
| Hariharan, V | 1 |
| Elmets, CA | 1 |
| Tyring, S | 1 |
| Kircik, LH | 5 |
| Yamauchi, P | 1 |
| Chen, H | 2 |
| Sun, J | 2 |
| Yang, H | 2 |
| Sun, Q | 1 |
| Zhang, J | 1 |
| Gu, J | 1 |
| Wen, H | 1 |
| Li, M | 1 |
| Liu, X | 2 |
| Lou, D | 1 |
| Erol, İ | 1 |
| Üstündağ Okur, N | 1 |
| Orak, D | 1 |
| Sipahi, H | 1 |
| Aydın, A | 1 |
| Özer, Ö | 1 |
| Elewski, B | 1 |
| Draelos, Z | 1 |
| Desai, SR | 2 |
| Alexis, AF | 2 |
| Hansen, JB | 1 |
| Patel, DS | 1 |
| Nyholm, N | 1 |
| Veverka, KA | 1 |
| Swensen, AR | 1 |
| Glick, B | 1 |
| Guerin, A | 1 |
| Ayyagari, R | 1 |
| Joseph, G | 1 |
| He, C | 1 |
| Jin, H | 1 |
| Hu, F | 1 |
| Zhang, L | 2 |
| Zhang, S | 1 |
| He, Y | 1 |
| Yang, X | 1 |
| Wang, X | 1 |
| Ji, C | 1 |
| Lv, C | 1 |
| Miao, G | 1 |
| Li, X | 2 |
| Diao, Q | 1 |
| Li, L | 1 |
| Li, Y | 1 |
| Wang, R | 1 |
| Zhou, X | 1 |
| Xia, X | 1 |
| Yan, M | 1 |
| Song, J | 1 |
| Zhang, R | 1 |
| Geng, L | 1 |
| Zheng, M | 1 |
| Lu, Q | 1 |
| Lu, T | 1 |
| Shi, Y | 1 |
| Jing, H | 1 |
| Zhang, X | 1 |
| Shi, J | 1 |
| Xia, J | 1 |
| Gao, Y | 1 |
| Wang, Y | 1 |
| Papp, K | 1 |
| Pariser, DM | 7 |
| Harris, S | 3 |
| Xi, C | 1 |
| Xiong, C | 1 |
| Wang, H | 1 |
| Liu, Y | 1 |
| Luo, S | 1 |
| Drew, S | 1 |
| Koo, K | 1 |
| Jeon, C | 1 |
| Bhutani, T | 1 |
| Prasad, V | 1 |
| Chaurasia, S | 1 |
| Gold, LS | 3 |
| Martin, G | 5 |
| Ramakrishna, T | 1 |
| Dayal, S | 1 |
| Kaura, R | 1 |
| Sahu, P | 1 |
| Jain, VK | 1 |
| Green, LJ | 2 |
| Weiss, J | 1 |
| Yamauchi, PS | 2 |
| Pariser, D | 1 |
| Kang, R | 1 |
| Heath, MS | 1 |
| Sahni, DR | 1 |
| Curry, ZA | 1 |
| Feldman, SR | 4 |
| Tanghetti, E | 1 |
| Papp, KA | 2 |
| Pharm, TL | 1 |
| Blauvelt, A | 1 |
| Stein Gold, LF | 2 |
| Radonjic, A | 1 |
| Evans, EL | 1 |
| Elmowafy, E | 1 |
| El-Gogary, RI | 1 |
| Ragai, MH | 1 |
| Nasr, M | 2 |
| Huang, YC | 1 |
| Chou, CL | 1 |
| Chiang, YY | 1 |
| Tidman, MJ | 1 |
| Yu, RX | 1 |
| Hui, Y | 1 |
| Li, CR | 1 |
| Dou, W | 1 |
| Zhao, Y | 1 |
| Hu, J | 1 |
| Piraccini, BM | 1 |
| Venturi, M | 1 |
| Patrizi, A | 1 |
| Hoffman, MB | 1 |
| Farhangian, M | 1 |
| Bangsgaard, N | 1 |
| Rørbye, C | 1 |
| Skov, L | 1 |
| Abdelgawad, R | 1 |
| Moftah, NH | 1 |
| Hamza, MY | 1 |
| Alexander, BJ | 1 |
| Thielen, AM | 1 |
| Laffitte, E | 1 |
| Kumar, U | 2 |
| Kaur, I | 2 |
| Dogra, S | 2 |
| De, D | 1 |
| Kumar, B | 1 |
| Bailey, J | 1 |
| Whitehair, B | 1 |
| Talpur, R | 1 |
| Cox, K | 1 |
| Duvic, M | 9 |
| Dhanabal, SP | 1 |
| Priyanka Dwarampudi, L | 1 |
| Muruganantham, N | 1 |
| Vadivelan, R | 1 |
| Fischer-Levancini, C | 1 |
| Sánchez-Regaña, M | 1 |
| Llambí, F | 1 |
| Collgros, H | 1 |
| Expósito-Serrano, V | 1 |
| Umbert-Millet, P | 1 |
| Tzaneva, S | 1 |
| Hönigsmann, H | 1 |
| Tanew, A | 1 |
| Seeber, A | 1 |
| Guenther, LC | 3 |
| Bruner, CR | 1 |
| Ventrapragada, M | 1 |
| Fleischer, AB | 2 |
| Weinstein, GD | 8 |
| Koo, JY | 6 |
| Krueger, GG | 3 |
| Lowe, NJ | 6 |
| Menter, MA | 1 |
| Lew-Kaya, DA | 6 |
| Sefton, J | 7 |
| Gibson, JR | 5 |
| Walker, PS | 1 |
| Veraldi, S | 2 |
| Schianchi, R | 1 |
| Bianchi, L | 1 |
| Soda, R | 2 |
| Diluvio, L | 1 |
| Chimenti, S | 2 |
| Cather, JC | 2 |
| Abramovits, W | 1 |
| Koo, J | 2 |
| Behnam, SE | 1 |
| Behnam, SM | 1 |
| Henno, A | 1 |
| Hua, MT | 1 |
| de la Brassinne, M | 1 |
| Lorette, G | 1 |
| Fontès, V | 1 |
| van de Kerkhof, PC | 1 |
| Vissers, WH | 1 |
| Saini, R | 1 |
| Tutrone, WD | 1 |
| Weinberg, JM | 1 |
| Naldi, L | 2 |
| Rzany, B | 2 |
| Friedlander, SF | 1 |
| Lee, E | 1 |
| Tzung, TY | 1 |
| Wu, JC | 1 |
| Hsu, NJ | 1 |
| Chen, YH | 1 |
| Ger, LP | 1 |
| Dando, TM | 1 |
| Wellington, K | 1 |
| Caputo, R | 1 |
| Pacifico, A | 1 |
| Peris, K | 1 |
| Weindl, G | 1 |
| Roeder, A | 1 |
| Schäfer-Korting, M | 1 |
| Schaller, M | 1 |
| Korting, HC | 1 |
| Wang, QY | 1 |
| Yan, HL | 1 |
| Liu, P | 1 |
| Peng, ZH | 1 |
| Tan, SS | 1 |
| Ceović, R | 1 |
| Pasić, A | 1 |
| Lipozencić, J | 1 |
| Murat-Susić, S | 1 |
| Skerlev, M | 1 |
| Husar, K | 1 |
| Kostović, K | 1 |
| Rigopoulos, D | 1 |
| Gregoriou, S | 1 |
| Katsambas, A | 1 |
| Waller, JM | 1 |
| Murase, JE | 1 |
| Dyson, SW | 1 |
| Kelly, KM | 1 |
| Jiaravuthisan, MM | 1 |
| Sasseville, D | 1 |
| Vender, RB | 1 |
| Murphy, F | 1 |
| Muhn, CY | 1 |
| Hsia, E | 1 |
| Johnston, MJ | 1 |
| Houlden, RJ | 1 |
| Chern, WH | 1 |
| Hofland, HE | 1 |
| Narang, T | 1 |
| Kanwar, AJ | 1 |
| Esgleyes-Ribot, T | 1 |
| Chandraratna, RA | 11 |
| Nagpal, S | 4 |
| Patel, S | 3 |
| Asano, AT | 4 |
| Johnson, AT | 1 |
| Thacher, SM | 1 |
| Friant, S | 1 |
| Malhotra, M | 2 |
| Shafer, J | 1 |
| Krasinski, G | 1 |
| Teng, M | 2 |
| Marks, R | 5 |
| Jacobe, H | 1 |
| DiSepio, D | 1 |
| Ghosn, C | 1 |
| Friedman, DJ | 1 |
| Jegasothy, BV | 1 |
| Jorizzo, JL | 1 |
| Shmunes, E | 1 |
| Tschen, EH | 1 |
| Lue, JC | 5 |
| McClelland, PB | 2 |
| Drake, LA | 1 |
| Elias, PM | 1 |
| Guzzo, C | 1 |
| Ast, E | 1 |
| Callen, JP | 1 |
| Cullen, SI | 1 |
| Hong, SR | 1 |
| Kulp-Shorten, CL | 1 |
| Phillips, TJ | 1 |
| Rosen, T | 1 |
| Wolf, DI | 1 |
| Quell, JM | 1 |
| Wollina, U | 1 |
| Breneman, DL | 1 |
| Goffe, BS | 1 |
| Grossman, JR | 1 |
| Ling, MR | 1 |
| Milbauer, J | 1 |
| Pincus, SH | 1 |
| Sibbald, RG | 1 |
| Swinyer, LJ | 1 |
| Hager, C | 1 |
| Mays, S | 1 |
| Poulin, Y | 1 |
| Poulin, YP | 2 |
| Federman, DG | 1 |
| Froelich, CW | 1 |
| Kirsner, RS | 1 |
| Dekle, CL | 1 |
| Behrens, S | 2 |
| Grundmann-Kollmann, M | 2 |
| Peter, RU | 3 |
| Kerscher, M | 3 |
| Gollnick, HP | 1 |
| Finzi, AF | 1 |
| Barker, JN | 1 |
| Jansen, C | 1 |
| Revuz, J | 1 |
| Saurat, J | 1 |
| Sander, P | 1 |
| Happe, M | 1 |
| Stücker, M | 2 |
| Hermes, N | 1 |
| Hoffmann, K | 1 |
| Altmeyer, P | 2 |
| Tang-Liu, DD | 1 |
| Matsumoto, RM | 1 |
| Usansky, JI | 1 |
| Hecker, D | 2 |
| Worsley, J | 2 |
| Yueh, G | 2 |
| Kuroda, K | 2 |
| Trozak, DJ | 1 |
| Linden, KG | 1 |
| Schiener, R | 2 |
| Cooper, CW | 1 |
| Gollnick, H | 1 |
| Smith, KC | 1 |
| Vasilopoulos, AI | 1 |
| Behrens-Williams, SC | 1 |
| Pillekamp, H | 1 |
| Kaskel, P | 1 |
| Coynik, D | 1 |
| Lombardi, K | 1 |
| Tan, MH | 1 |
| Feldman, S | 1 |
| Sapadin, A | 1 |
| Shoji, T | 1 |
| Fleischmajer, R | 1 |
| Martin, D | 1 |
| Scher, RK | 1 |
| Stiller, M | 1 |
| Zhu, YI | 1 |
| Hoffmann, M | 1 |
| Bowman, PH | 1 |
| Maloney, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Excimer Laser Combined With Either Topical Tazarotene or Topical Betamethasone Valerate Versus Excimer Laser Alone in Treatment of Localized Chronic Plaque Psoriasis; Clinical and Dermoscopic Study[NCT05555797] | Phase 4 | 30 participants (Anticipated) | Interventional | 2022-10-30 | Not yet recruiting | ||
| Investigator-Initiated, Open Label Trial of a Combination of Halobetasol Propionate 0.01% Andtazarotene 0.045% Lotion (Duobrii®) for Plaque Type Psoriasis of the Hands and/or Feet[NCT04720105] | Phase 4 | 22 participants (Actual) | Interventional | 2020-11-19 | Completed | ||
| The Efficacy and Safety of Topical Methotrexate Microemulsion in Combination With Excimer Light and Narrow Band-ultraviolet B in the Treatment of Plaque Psoriasis[NCT04971239] | Phase 4 | 30 participants (Anticipated) | Interventional | 2021-10-01 | Not yet recruiting | ||
| Comparison of Safety and Efficacy of Tazarotene 0.1% Plus Clindamycin 1% Gel vs. Adapalene 0.1% Plus Clindamycin 1% Gel in the Treatment of Facial Acne Vulgaris: A Randomized Controlled Trial[NCT02721173] | Phase 4 | 60 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study.[NCT03263624] | Phase 4 | 30 participants (Anticipated) | Interventional | 2017-10-01 | Not yet recruiting | ||
| Spray® and Vectical Ointment® in the Treatment of Plaque Psoriasis[NCT01205880] | Phase 4 | 12 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Subclinical Nail Involvement in Relevant Skin Diseases[NCT04092413] | 384 participants (Anticipated) | Observational | 2019-11-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patient-reported outcomes evaluated by Dermatology Quality of Life Index (DLQI). DLQi is a 10-item questionnaire, each question is scored from 0 to 3, giving a possible score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life). Higher score indicates poorer health outcome. (NCT04720105)
Timeframe: Baseline and Week 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Week 24 | |
| Participants With Plaque Type Psoriasis | 6.24 | 4.94 |
Treatment satisfaction evaluated by a Numerical Rating Scale (NRS). Full scale from 0 to 10, higher score indicates poorer health outcome. (NCT04720105)
Timeframe: Baseline and Week 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Week 24 | |
| Participants With Plaque Type Psoriasis | 1.35 | 1.29 |
Number of participants achieving Palmoplantar Physician Global Assessment (ppPGA) of 0 (clear) or 1 (almost clear/minimal) after 24 weeks of treatment. The ppPGA is based on the Investigators Global Assessment (IGA) modified version 11, specifically applied to the hands and/or feet: 0 (clear), 1 (almost clear/minimal), 2 (mild), 3 (moderate), 4 (marked/moderate-to-severe), 5 (severe) (NCT04720105)
Timeframe: Baseline and Week 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Week 24 | |
| Participants With Plaque Type Psoriasis | 3.47 | 2.24 |
53 reviews available for tazarotene and Psoriasis
| Article | Year |
|---|---|
Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion.
Topics: Clobetasol; Dermatologic Agents; Drug Combinations; Emollients; Emulsions; Humans; Motivation; Nicot | 2023 |
Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion.
Topics: Clobetasol; Dermatologic Agents; Drug Combinations; Emollients; Emulsions; Humans; Motivation; Nicot | 2023 |
Breaking the Frustrating Cycle of Topical Steroids in Psoriasis: A Review of a Novel Vehicle for Fixed-Dose Combination Halobetasol Propionate/Tazarotene.
Topics: Excipients; Humans; Propionates; Psoriasis; Steroids | 2023 |
Breaking the Frustrating Cycle of Topical Steroids in Psoriasis: A Review of a Novel Vehicle for Fixed-Dose Combination Halobetasol Propionate/Tazarotene.
Topics: Excipients; Humans; Propionates; Psoriasis; Steroids | 2023 |
Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis.
Topics: Administration, Topical; Calcitriol; Clobetasol; Databases, Factual; Dermatologic Agents; Humans; Ni | 2017 |
Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis.
Topics: Administration, Topical; Calcitriol; Clobetasol; Databases, Factual; Dermatologic Agents; Humans; Ni | 2017 |
Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
Topics: Clinical Trials, Phase III as Topic; Clobetasol; Dermatitis; Dermatologic Agents; Drug Combinations; | 2018 |
Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
Topics: Clinical Trials, Phase III as Topic; Clobetasol; Dermatitis; Dermatologic Agents; Drug Combinations; | 2018 |
Pharmacokinetics of tazarotene and acitretin in psoriasis.
Topics: Acitretin; Administration, Cutaneous; Administration, Oral; Animals; Dermatologic Agents; Humans; Ke | 2018 |
Pharmacokinetics of tazarotene and acitretin in psoriasis.
Topics: Acitretin; Administration, Cutaneous; Administration, Oral; Animals; Dermatologic Agents; Humans; Ke | 2018 |
Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy
Topics: Administration, Cutaneous; Dermatologic Agents; Gels; Humans; Nicotinic Acids; Psoriasis; Severity o | 2018 |
Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy
Topics: Administration, Cutaneous; Dermatologic Agents; Gels; Humans; Nicotinic Acids; Psoriasis; Severity o | 2018 |
Psoriasis during pregnancy: characteristics and important management recommendations.
Topics: Adrenal Cortex Hormones; Animals; Contraindications; Female; Humans; Male; Nicotinic Acids; Photothe | 2015 |
Psoriasis during pregnancy: characteristics and important management recommendations.
Topics: Adrenal Cortex Hormones; Animals; Contraindications; Female; Humans; Male; Nicotinic Acids; Photothe | 2015 |
Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments.
Topics: Acitretin; Administration, Cutaneous; Adrenal Cortex Hormones; Calcineurin Inhibitors; Calcitriol; C | 2015 |
Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments.
Topics: Acitretin; Administration, Cutaneous; Adrenal Cortex Hormones; Calcineurin Inhibitors; Calcitriol; C | 2015 |
Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence.
Topics: Administration, Cutaneous; Anthralin; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinati | 2016 |
Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence.
Topics: Administration, Cutaneous; Anthralin; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinati | 2016 |
[Topical treatments for psoriasis in 2009].
Topics: Administration, Cutaneous; Anthralin; Calcitriol; Dermatologic Agents; Drug Administration Schedule; | 2009 |
[Topical treatments for psoriasis in 2009].
Topics: Administration, Cutaneous; Anthralin; Calcitriol; Dermatologic Agents; Drug Administration Schedule; | 2009 |
Efficacy and safety of topical tazarotene: a review.
Topics: Acne Vulgaris; Administration, Cutaneous; Animals; Carcinoma, Basal Cell; Dermatologic Agents; Human | 2009 |
Efficacy and safety of topical tazarotene: a review.
Topics: Acne Vulgaris; Administration, Cutaneous; Animals; Carcinoma, Basal Cell; Dermatologic Agents; Human | 2009 |
Optimizing treatment with topical tazarotene.
Topics: Acne Vulgaris; Administration, Topical; Adrenal Cortex Hormones; Calcitriol; Dose-Response Relations | 2003 |
Optimizing treatment with topical tazarotene.
Topics: Acne Vulgaris; Administration, Topical; Adrenal Cortex Hormones; Calcitriol; Dose-Response Relations | 2003 |
A systematic review of adverse effects associated with topical treatments for psoriasis.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Calcitriol; Coal Tar; Dermatologic Agen | 2003 |
A systematic review of adverse effects associated with topical treatments for psoriasis.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Calcitriol; Coal Tar; Dermatologic Agen | 2003 |
The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis.
Topics: Administration, Cutaneous; Clinical Trials as Topic; Dermatologic Agents; Drug Stability; Drug Thera | 2003 |
The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis.
Topics: Administration, Cutaneous; Clinical Trials as Topic; Dermatologic Agents; Drug Stability; Drug Thera | 2003 |
[Medication of the month. Tazarotene 0.05%-0.1% (Zorac)].
Topics: Administration, Topical; Dermatologic Agents; Dose-Response Relationship, Drug; Humans; Ichthyosis; | 2003 |
[Medication of the month. Tazarotene 0.05%-0.1% (Zorac)].
Topics: Administration, Topical; Dermatologic Agents; Dose-Response Relationship, Drug; Humans; Ichthyosis; | 2003 |
[Prescribe topical treatments for psoriasis].
Topics: Administration, Topical; Cholecalciferol; Dermatologic Agents; Drug Hypersensitivity; Humans; Nicoti | 2004 |
[Prescribe topical treatments for psoriasis].
Topics: Administration, Topical; Cholecalciferol; Dermatologic Agents; Drug Hypersensitivity; Humans; Nicoti | 2004 |
Established treatments of psoriasis.
Topics: Cholecalciferol; Coal Tar; Humans; Nicotinic Acids; Phototherapy; Psoriasis | 2004 |
Established treatments of psoriasis.
Topics: Cholecalciferol; Coal Tar; Humans; Nicotinic Acids; Phototherapy; Psoriasis | 2004 |
Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.
Topics: Adalimumab; Administration, Oral; Alefacept; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal | 2005 |
Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.
Topics: Adalimumab; Administration, Oral; Alefacept; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal | 2005 |
Chronic plaque psoriasis.
Topics: Anthralin; Combined Modality Therapy; Cyclosporine; Dermatologic Agents; Ficusin; Humans; Nicotinic | 2004 |
Chronic plaque psoriasis.
Topics: Anthralin; Combined Modality Therapy; Cyclosporine; Dermatologic Agents; Ficusin; Humans; Nicotinic | 2004 |
Potential future therapies for psoriasis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Cyclospo | 2005 |
Potential future therapies for psoriasis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Cyclospo | 2005 |
Corticosteroids: options in the era of steroid-sparing therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Calcineurin Inhib | 2005 |
Corticosteroids: options in the era of steroid-sparing therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Calcineurin Inhib | 2005 |
Topical tazarotene: a review of its use in the treatment of plaque psoriasis.
Topics: Administration, Topical; Adrenal Cortex Hormones; Combined Modality Therapy; Humans; Keratolytic Age | 2005 |
Topical tazarotene: a review of its use in the treatment of plaque psoriasis.
Topics: Administration, Topical; Adrenal Cortex Hormones; Combined Modality Therapy; Humans; Keratolytic Age | 2005 |
Receptor-selective retinoids for psoriasis: focus on tazarotene.
Topics: Animals; Clinical Trials as Topic; Dermatologic Agents; Female; Humans; Male; Nicotinic Acids; Psori | 2006 |
Receptor-selective retinoids for psoriasis: focus on tazarotene.
Topics: Animals; Clinical Trials as Topic; Dermatologic Agents; Female; Humans; Male; Nicotinic Acids; Psori | 2006 |
Chronic plaque psoriasis.
Topics: Adrenal Cortex Hormones; Alefacept; Anthralin; Antibodies, Monoclonal; Antibodies, Monoclonal, Human | 2006 |
Chronic plaque psoriasis.
Topics: Adrenal Cortex Hormones; Alefacept; Anthralin; Antibodies, Monoclonal; Antibodies, Monoclonal, Human | 2006 |
Treatment of childhood psoriasis.
Topics: Adrenal Cortex Hormones; Anthralin; Calcitriol; Child; Cyclosporine; Humans; Methotrexate; Nicotinic | 2006 |
Treatment of childhood psoriasis.
Topics: Adrenal Cortex Hormones; Anthralin; Calcitriol; Child; Cyclosporine; Humans; Methotrexate; Nicotinic | 2006 |
Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Clinical Trials as Topic; Cyclosporine; | 2007 |
Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Clinical Trials as Topic; Cyclosporine; | 2007 |
Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Clinical Trials as Topic; Cyclosporine; | 2007 |
Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Clinical Trials as Topic; Cyclosporine; | 2007 |
Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Clinical Trials as Topic; Cyclosporine; | 2007 |
Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Clinical Trials as Topic; Cyclosporine; | 2007 |
Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Clinical Trials as Topic; Cyclosporine; | 2007 |
Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Clinical Trials as Topic; Cyclosporine; | 2007 |
Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis.
Topics: Administration, Topical; Animals; Dermatologic Agents; Humans; Nicotinic Acids; Prodrugs; Psoriasis; | 1997 |
Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis.
Topics: Administration, Topical; Animals; Dermatologic Agents; Humans; Nicotinic Acids; Prodrugs; Psoriasis; | 1997 |
Molecular mechanisms of tazarotene action in psoriasis.
Topics: Cell Differentiation; Cell Division; Dermatologic Agents; Humans; Keratinocytes; Nicotinic Acids; Pr | 1997 |
Molecular mechanisms of tazarotene action in psoriasis.
Topics: Cell Differentiation; Cell Division; Dermatologic Agents; Humans; Keratinocytes; Nicotinic Acids; Pr | 1997 |
Clinical safety of tazarotene in the treatment of plaque psoriasis.
Topics: Administration, Oral; Administration, Topical; Animals; Dermatologic Agents; Humans; Nicotinic Acids | 1997 |
Clinical safety of tazarotene in the treatment of plaque psoriasis.
Topics: Administration, Oral; Administration, Topical; Animals; Dermatologic Agents; Humans; Nicotinic Acids | 1997 |
Tazarotene gel: efficacy and safety in plaque psoriasis.
Topics: Clinical Trials as Topic; Dermatologic Agents; Dose-Response Relationship, Drug; Gels; Humans; Nicot | 1997 |
Tazarotene gel: efficacy and safety in plaque psoriasis.
Topics: Clinical Trials as Topic; Dermatologic Agents; Dose-Response Relationship, Drug; Gels; Humans; Nicot | 1997 |
Rational design of receptor-selective retinoids.
Topics: Administration, Cutaneous; Drug Design; Humans; Keratolytic Agents; Nicotinic Acids; Psoriasis; Rece | 1998 |
Rational design of receptor-selective retinoids.
Topics: Administration, Cutaneous; Drug Design; Humans; Keratolytic Agents; Nicotinic Acids; Psoriasis; Rece | 1998 |
Pharmacokinetics and safety review of tazarotene.
Topics: Administration, Cutaneous; Humans; Keratolytic Agents; Nicotinic Acids; Psoriasis | 1998 |
Pharmacokinetics and safety review of tazarotene.
Topics: Administration, Cutaneous; Humans; Keratolytic Agents; Nicotinic Acids; Psoriasis | 1998 |
The pathogenesis of psoriasis and the mechanism of action of tazarotene.
Topics: Administration, Cutaneous; Biomarkers; Epidermal Growth Factor; Humans; Keratinocytes; Keratolytic A | 1998 |
The pathogenesis of psoriasis and the mechanism of action of tazarotene.
Topics: Administration, Cutaneous; Biomarkers; Epidermal Growth Factor; Humans; Keratinocytes; Keratolytic A | 1998 |
Tazarotene in combination with topical corticosteroids.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Clinical Trials as Topic; Drug Synergism; Drug T | 1998 |
Tazarotene in combination with topical corticosteroids.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Clinical Trials as Topic; Drug Synergism; Drug T | 1998 |
Tazarotene in combination with phototherapy.
Topics: Administration, Cutaneous; Humans; Keratolytic Agents; Nicotinic Acids; Photochemotherapy; Psoriasis | 1998 |
Tazarotene in combination with phototherapy.
Topics: Administration, Cutaneous; Humans; Keratolytic Agents; Nicotinic Acids; Photochemotherapy; Psoriasis | 1998 |
Pharmacologic profile of tazarotene.
Topics: Administration, Topical; Animals; Clinical Trials as Topic; Dermatologic Agents; Female; Humans; Mal | 1998 |
Pharmacologic profile of tazarotene.
Topics: Administration, Topical; Animals; Clinical Trials as Topic; Dermatologic Agents; Female; Humans; Mal | 1998 |
Clinical efficacy and safety of tazarotene: optimizing clinical results.
Topics: Administration, Topical; Adrenal Cortex Hormones; Clinical Trials as Topic; Dermatologic Agents; Dos | 1998 |
Clinical efficacy and safety of tazarotene: optimizing clinical results.
Topics: Administration, Topical; Adrenal Cortex Hormones; Clinical Trials as Topic; Dermatologic Agents; Dos | 1998 |
How and where tazarotene might fit into the current therapeutic armamentarium: an expert opinion.
Topics: Administration, Topical; Dermatologic Agents; Follow-Up Studies; Humans; Nicotinic Acids; Psoriasis; | 1998 |
How and where tazarotene might fit into the current therapeutic armamentarium: an expert opinion.
Topics: Administration, Topical; Dermatologic Agents; Follow-Up Studies; Humans; Nicotinic Acids; Psoriasis; | 1998 |
The management of psoriasis-tazarotene: the bottom line.
Topics: Administration, Topical; Clinical Trials as Topic; Dermatologic Agents; Humans; Nicotinic Acids; Pro | 1998 |
The management of psoriasis-tazarotene: the bottom line.
Topics: Administration, Topical; Clinical Trials as Topic; Dermatologic Agents; Humans; Nicotinic Acids; Pro | 1998 |
Current research and future developments in retinoids: oral and topical agents.
Topics: Administration, Oral; Administration, Topical; Animals; California; Forecasting; Guinea Pigs; Humans | 1998 |
Current research and future developments in retinoids: oral and topical agents.
Topics: Administration, Oral; Administration, Topical; Animals; California; Forecasting; Guinea Pigs; Humans | 1998 |
Topical psoriasis therapy.
Topics: Administration, Cutaneous; Administration, Topical; Anthralin; Anti-Inflammatory Agents; Calcitriol; | 1999 |
Topical psoriasis therapy.
Topics: Administration, Cutaneous; Administration, Topical; Anthralin; Anti-Inflammatory Agents; Calcitriol; | 1999 |
Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis.
Topics: Acne Vulgaris; Administration, Topical; Animals; Clinical Trials as Topic; Dermatologic Agents; Huma | 1999 |
Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis.
Topics: Acne Vulgaris; Administration, Topical; Animals; Clinical Trials as Topic; Dermatologic Agents; Huma | 1999 |
Topical corticosteroid therapy in psoriasis vulgaris: update and new strategies.
Topics: Administration, Topical; Anti-Inflammatory Agents; Calcitriol; Dermatologic Agents; Drug Therapy, Co | 1999 |
Topical corticosteroid therapy in psoriasis vulgaris: update and new strategies.
Topics: Administration, Topical; Anti-Inflammatory Agents; Calcitriol; Dermatologic Agents; Drug Therapy, Co | 1999 |
Psoriasis: current perspectives with an emphasis on treatment.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Calcitriol; Cyclosporine; Dermatologic Agents; D | 1999 |
Psoriasis: current perspectives with an emphasis on treatment.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Calcitriol; Cyclosporine; Dermatologic Agents; D | 1999 |
Tazarotene--a topical retinoid for psoriasis.
Topics: Clinical Trials as Topic; Dermatologic Agents; Gels; Humans; Nicotinic Acids; Prodrugs; Psoriasis; R | 1999 |
Tazarotene--a topical retinoid for psoriasis.
Topics: Clinical Trials as Topic; Dermatologic Agents; Gels; Humans; Nicotinic Acids; Prodrugs; Psoriasis; R | 1999 |
New topicals for mild and moderate psoriasis.
Topics: Administration, Topical; Calcitriol; Dermatologic Agents; Humans; Nicotinic Acids; Psoriasis | 1999 |
New topicals for mild and moderate psoriasis.
Topics: Administration, Topical; Calcitriol; Dermatologic Agents; Humans; Nicotinic Acids; Psoriasis | 1999 |
The role of tazarotene in the treatment of psoriasis.
Topics: Administration, Topical; Dermatologic Agents; Fluocinonide; Humans; Nicotinic Acids; Psoriasis | 1999 |
The role of tazarotene in the treatment of psoriasis.
Topics: Administration, Topical; Dermatologic Agents; Fluocinonide; Humans; Nicotinic Acids; Psoriasis | 1999 |
Topical antipsoriatics.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Anti-Inflammatory Agents; Calcitriol; D | 2000 |
Topical antipsoriatics.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Anti-Inflammatory Agents; Calcitriol; D | 2000 |
Pharmacokinetics and safety of tazarotene.
Topics: Acne Vulgaris; Biological Availability; Biotransformation; Dose-Response Relationship, Drug; Humans; | 2000 |
Pharmacokinetics and safety of tazarotene.
Topics: Acne Vulgaris; Biological Availability; Biotransformation; Dose-Response Relationship, Drug; Humans; | 2000 |
Tazarotene combination treatments in psoriasis.
Topics: Adrenal Cortex Hormones; Calcitriol; Drug Therapy, Combination; Humans; Keratolytic Agents; Nicotini | 2000 |
Tazarotene combination treatments in psoriasis.
Topics: Adrenal Cortex Hormones; Calcitriol; Drug Therapy, Combination; Humans; Keratolytic Agents; Nicotini | 2000 |
Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid.
Topics: Adrenal Cortex Hormones; Drug Therapy, Combination; Humans; Keratolytic Agents; Nicotinic Acids; Pso | 2000 |
Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid.
Topics: Adrenal Cortex Hormones; Drug Therapy, Combination; Humans; Keratolytic Agents; Nicotinic Acids; Pso | 2000 |
Advances in psoriasis treatment.
Topics: Acitretin; Administration, Topical; Anthralin; Anti-Inflammatory Agents; Coal Tar; Cyclosporine; Der | 2000 |
Advances in psoriasis treatment.
Topics: Acitretin; Administration, Topical; Anthralin; Anti-Inflammatory Agents; Coal Tar; Cyclosporine; Der | 2000 |
Topical tazarotene therapy for psoriasis, acne vulgaris, and photoaging.
Topics: Acne Vulgaris; Administration, Topical; Humans; Nicotinic Acids; Psoriasis; Retinoids; Skin Aging | 2002 |
Topical tazarotene therapy for psoriasis, acne vulgaris, and photoaging.
Topics: Acne Vulgaris; Administration, Topical; Humans; Nicotinic Acids; Psoriasis; Retinoids; Skin Aging | 2002 |
54 trials available for tazarotene and Psoriasis
| Article | Year |
|---|---|
Efficacy of combined fractional carbon dioxide laser and topical tazarotene in nail psoriasis treatment: A randomized intrapatient left-to-right study.
Topics: Dermatologic Agents; Humans; Lasers, Gas; Nail Diseases; Nicotinic Acids; Psoriasis; Treatment Outco | 2022 |
Efficacy of combined fractional carbon dioxide laser and topical tazarotene in nail psoriasis treatment: A randomized intrapatient left-to-right study.
Topics: Dermatologic Agents; Humans; Lasers, Gas; Nail Diseases; Nicotinic Acids; Psoriasis; Treatment Outco | 2022 |
Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
Topics: Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Follow-Up Studies; Humans; | 2019 |
Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
Topics: Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Follow-Up Studies; Humans; | 2019 |
Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials
Topics: Adult; Clobetasol; Dermatitis, Contact; Dermatologic Agents; Double-Blind Method; Drug Combinations; | 2019 |
Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials
Topics: Adult; Clobetasol; Dermatitis, Contact; Dermatologic Agents; Double-Blind Method; Drug Combinations; | 2019 |
Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities.
Topics: Administration, Cutaneous; Adult; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combina | 2020 |
Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities.
Topics: Administration, Cutaneous; Adult; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combina | 2020 |
Fixed combination of tazarotene and betamethasone dipropionate for treatment of psoriasis vulgaris: The result of a phase 3, multicenter, randomized controlled trial.
Topics: Betamethasone; Clobetasol; Dermatologic Agents; Double-Blind Method; Humans; Neoplasm Recurrence, Lo | 2020 |
Fixed combination of tazarotene and betamethasone dipropionate for treatment of psoriasis vulgaris: The result of a phase 3, multicenter, randomized controlled trial.
Topics: Betamethasone; Clobetasol; Dermatologic Agents; Double-Blind Method; Humans; Neoplasm Recurrence, Lo | 2020 |
Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females.
Topics: Adult; Aged; Clobetasol; Dermatitis, Contact; Double-Blind Method; Drug Combinations; Female; Humans | 2020 |
Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females.
Topics: Adult; Aged; Clobetasol; Dermatitis, Contact; Double-Blind Method; Drug Combinations; Female; Humans | 2020 |
Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study.
Topics: Administration, Cutaneous; Adult; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combina | 2021 |
Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study.
Topics: Administration, Cutaneous; Adult; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combina | 2021 |
Fixed-Combination Halobetasol Propionate and Tazarotene Lotion for Psoriasis in Patients With Skin of Color.
Topics: Adult; Clobetasol; Color; Dermatologic Agents; Drug Combinations; Humans; Nicotinic Acids; Psoriasis | 2021 |
Fixed-Combination Halobetasol Propionate and Tazarotene Lotion for Psoriasis in Patients With Skin of Color.
Topics: Adult; Clobetasol; Color; Dermatologic Agents; Drug Combinations; Humans; Nicotinic Acids; Psoriasis | 2021 |
Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%-5% Affected Body Surface Area.
Topics: Body Surface Area; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Humans; | 2021 |
Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%-5% Affected Body Surface Area.
Topics: Body Surface Area; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Humans; | 2021 |
Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
Topics: Administration, Cutaneous; Chronic Disease; Clobetasol; Dermatologic Agents; Double-Blind Method; Dr | 2018 |
Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
Topics: Administration, Cutaneous; Chronic Disease; Clobetasol; Dermatologic Agents; Double-Blind Method; Dr | 2018 |
Tazarotene gel with narrow-band UVB phototherapy: a synergistic combination in psoriasis.
Topics: Adolescent; Adult; Combined Modality Therapy; Dermatologic Agents; Female; Follow-Up Studies; Humans | 2018 |
Tazarotene gel with narrow-band UVB phototherapy: a synergistic combination in psoriasis.
Topics: Adolescent; Adult; Combined Modality Therapy; Dermatologic Agents; Female; Follow-Up Studies; Humans | 2018 |
Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
Topics: Administration, Cutaneous; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; | 2018 |
Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
Topics: Administration, Cutaneous; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; | 2018 |
Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.
Topics: Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Drug Compounding; Humans; N | 2018 |
Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.
Topics: Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Drug Compounding; Humans; N | 2018 |
Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis.
Topics: Adult; Aged; Aged, 80 and over; Clobetasol; Dermatologic Agents; Drug Therapy, Combination; Humans; | 2019 |
Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis.
Topics: Adult; Aged; Aged, 80 and over; Clobetasol; Dermatologic Agents; Drug Therapy, Combination; Humans; | 2019 |
Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis
Topics: Administration, Cutaneous; Clobetasol; Dermatologic Agents; Drug Combinations; Emulsions; Humans; Ni | 2018 |
Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis
Topics: Administration, Cutaneous; Clobetasol; Dermatologic Agents; Drug Combinations; Emulsions; Humans; Ni | 2018 |
Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis
Topics: Administration, Cutaneous; Clobetasol; Dermatologic Agents; Drug Combinations; Drug Synergism; Follo | 2019 |
Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis
Topics: Administration, Cutaneous; Clobetasol; Dermatologic Agents; Drug Combinations; Drug Synergism; Follo | 2019 |
Novel antipsoriatic fluidized spanlastic nanovesicles: In vitro physicochemical characterization, ex vivo cutaneous retention and exploratory clinical therapeutic efficacy.
Topics: Administration, Cutaneous; Adult; Animals; Dermatologic Agents; Eucalyptol; Female; Hexoses; Humans; | 2019 |
Novel antipsoriatic fluidized spanlastic nanovesicles: In vitro physicochemical characterization, ex vivo cutaneous retention and exploratory clinical therapeutic efficacy.
Topics: Administration, Cutaneous; Adult; Animals; Dermatologic Agents; Eucalyptol; Female; Hexoses; Humans; | 2019 |
Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: a single-blind, intrapatient left-to-right controlled study.
Topics: Administration, Topical; Adult; Aged; Combined Modality Therapy; Dermatologic Agents; Drug Administr | 2013 |
Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: a single-blind, intrapatient left-to-right controlled study.
Topics: Administration, Topical; Adult; Aged; Combined Modality Therapy; Dermatologic Agents; Drug Administr | 2013 |
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Topics: Administration, Cutaneous; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; | 2017 |
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Topics: Administration, Cutaneous; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; | 2017 |
Topical tazarotene vs. coal tar in stable plaque psoriasis.
Topics: Administration, Topical; Adult; Coal Tar; Dermatologic Agents; Humans; Keratolytic Agents; Nicotinic | 2010 |
Topical tazarotene vs. coal tar in stable plaque psoriasis.
Topics: Administration, Topical; Adult; Coal Tar; Dermatologic Agents; Humans; Keratolytic Agents; Nicotinic | 2010 |
A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis.
Topics: Adult; Chronic Disease; Combined Modality Therapy; Dermatologic Agents; Dihydroxycholecalciferols; F | 2002 |
A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis.
Topics: Adult; Chronic Disease; Combined Modality Therapy; Dermatologic Agents; Dihydroxycholecalciferols; F | 2002 |
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Dermatologic Agents; Double-Bli | 2003 |
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Dermatologic Agents; Double-Bli | 2003 |
Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study.
Topics: Adult; Aged; Dermatologic Agents; Female; Humans; Male; Middle Aged; Nail Diseases; Nicotinic Acids; | 2003 |
Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study.
Topics: Adult; Aged; Dermatologic Agents; Female; Humans; Male; Middle Aged; Nail Diseases; Nicotinic Acids; | 2003 |
Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Calcitriol; Child; Dermatolog | 2005 |
Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Calcitriol; Child; Dermatolog | 2005 |
Short contact therapy with tazarotene in psoriasis vulgaris.
Topics: Administration, Topical; Adult; Aged; Dermatitis, Irritant; Dermatologic Agents; Female; Gels; Human | 2006 |
Short contact therapy with tazarotene in psoriasis vulgaris.
Topics: Administration, Topical; Adult; Aged; Dermatitis, Irritant; Dermatologic Agents; Female; Gels; Human | 2006 |
[Inhibition of promyelocytic leukemia gene by tazarotene in hyperproliferative epidermis of psoriasis].
Topics: Adolescent; Adult; Double-Blind Method; Down-Regulation; Epidermis; Female; Gene Expression; Humans; | 2006 |
[Inhibition of promyelocytic leukemia gene by tazarotene in hyperproliferative epidermis of psoriasis].
Topics: Adolescent; Adult; Double-Blind Method; Down-Regulation; Epidermis; Female; Gene Expression; Humans; | 2006 |
Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study.
Topics: Administration, Topical; Clobetasol; Dermatologic Agents; Double-Blind Method; Humans; Keratolytic A | 2007 |
Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study.
Topics: Administration, Topical; Clobetasol; Dermatologic Agents; Double-Blind Method; Humans; Keratolytic A | 2007 |
Response of psoriasis to a new topical retinoid, AGN 190168.
Topics: Administration, Cutaneous; Adult; Antigens, CD; Biopsy; Cell Adhesion Molecules; Double-Blind Method | 1994 |
Response of psoriasis to a new topical retinoid, AGN 190168.
Topics: Administration, Cutaneous; Adult; Antigens, CD; Biopsy; Cell Adhesion Molecules; Double-Blind Method | 1994 |
Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis.
Topics: Administration, Cutaneous; Drug Administration Schedule; Gels; Humans; Nicotinic Acids; Psoriasis; S | 1996 |
Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis.
Topics: Administration, Cutaneous; Drug Administration Schedule; Gels; Humans; Nicotinic Acids; Psoriasis; S | 1996 |
Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Ge | 1997 |
Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Ge | 1997 |
The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis.
Topics: Administration, Cutaneous; Adult; Dermatologic Agents; Double-Blind Method; Drug Administration Sche | 1998 |
The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis.
Topics: Administration, Cutaneous; Adult; Dermatologic Agents; Double-Blind Method; Drug Administration Sche | 1998 |
Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-In | 1998 |
Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-In | 1998 |
Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Adult; Canada; Drug Therapy, Combination; Female | 1998 |
Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Adult; Canada; Drug Therapy, Combination; Female | 1998 |
Tazarotene in combination with topical corticosteroids.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Clinical Trials as Topic; Drug Synergism; Drug T | 1998 |
Tazarotene in combination with topical corticosteroids.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Clinical Trials as Topic; Drug Synergism; Drug T | 1998 |
Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study.
Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Dermatologic Agents; Drug Therapy, C | 1999 |
Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study.
Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Dermatologic Agents; Drug Therapy, C | 1999 |
The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Dermatologic Agents; Double-Blind Method; Female; Follow-Up Studies; | 1999 |
The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Dermatologic Agents; Double-Blind Method; Female; Follow-Up Studies; | 1999 |
Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptor-selective topical retinoid.
Topics: Combined Modality Therapy; Follow-Up Studies; Gels; Humans; Keratolytic Agents; Nicotinic Acids; Pso | 1999 |
Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptor-selective topical retinoid.
Topics: Combined Modality Therapy; Follow-Up Studies; Gels; Humans; Keratolytic Agents; Nicotinic Acids; Pso | 1999 |
[Tazarotene increases the antipsoriatic effect of dithranol in chronic psoriasis].
Topics: Anthralin; Chronic Disease; Dermatologic Agents; Drug Combinations; Drug Synergism; Female; Gels; Hu | 1999 |
[Tazarotene increases the antipsoriatic effect of dithranol in chronic psoriasis].
Topics: Anthralin; Chronic Disease; Dermatologic Agents; Drug Combinations; Drug Synergism; Female; Gels; Hu | 1999 |
Interactions between tazarotene and ultraviolet light.
Topics: Adult; Chronic Disease; Dermatologic Agents; Female; Gels; Humans; Male; Middle Aged; Nicotinic Acid | 1999 |
Interactions between tazarotene and ultraviolet light.
Topics: Adult; Chronic Disease; Dermatologic Agents; Female; Gels; Humans; Male; Middle Aged; Nicotinic Acid | 1999 |
Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel.
Topics: Administration, Cutaneous; Combined Modality Therapy; Dermatologic Agents; Gels; Humans; Nicotinic A | 2000 |
Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel.
Topics: Administration, Cutaneous; Combined Modality Therapy; Dermatologic Agents; Gels; Humans; Nicotinic A | 2000 |
Optimizing therapy: tazarotene in combination with phototherapy.
Topics: Adult; Aged; Combined Modality Therapy; Dermatologic Agents; Humans; Middle Aged; Nicotinic Acids; P | 1999 |
Optimizing therapy: tazarotene in combination with phototherapy.
Topics: Adult; Aged; Combined Modality Therapy; Dermatologic Agents; Humans; Middle Aged; Nicotinic Acids; P | 1999 |
Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis.
Topics: Adrenal Cortex Hormones; Adult; Analysis of Variance; Dermatologic Agents; Drug Combinations; Drug E | 1999 |
Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis.
Topics: Adrenal Cortex Hormones; Adult; Analysis of Variance; Dermatologic Agents; Drug Combinations; Drug E | 1999 |
Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid.
Topics: Adrenal Cortex Hormones; Drug Therapy, Combination; Humans; Keratolytic Agents; Nicotinic Acids; Pso | 2000 |
Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid.
Topics: Adrenal Cortex Hormones; Drug Therapy, Combination; Humans; Keratolytic Agents; Nicotinic Acids; Pso | 2000 |
Tazarotene plus UVB phototherapy in the treatment of psoriasis.
Topics: Administration, Topical; Adult; Aged; Combined Modality Therapy; Female; Humans; Male; Middle Aged; | 2000 |
Tazarotene plus UVB phototherapy in the treatment of psoriasis.
Topics: Administration, Topical; Adult; Aged; Combined Modality Therapy; Female; Humans; Male; Middle Aged; | 2000 |
A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Calcitriol; Dermatologic Agents; Drug Admi | 2000 |
A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Calcitriol; Dermatologic Agents; Drug Admi | 2000 |
Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis.
Topics: Administration, Topical; Adult; Calcitriol; Combined Modality Therapy; Dermatologic Agents; Female; | 2000 |
Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis.
Topics: Administration, Topical; Adult; Calcitriol; Combined Modality Therapy; Dermatologic Agents; Female; | 2000 |
An observation study evaluating the efficacy of tazarotene plus corticosteroid in treating plaque psoriasis in patients switched from treatment with calcipotriene +/- corticosteroid.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Calci | 2000 |
An observation study evaluating the efficacy of tazarotene plus corticosteroid in treating plaque psoriasis in patients switched from treatment with calcipotriene +/- corticosteroid.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Calci | 2000 |
Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment.
Topics: Administration, Topical; Anti-Inflammatory Agents; Calcitriol; Dermatologic Agents; Drug Therapy, Co | 2000 |
Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment.
Topics: Administration, Topical; Anti-Inflammatory Agents; Calcitriol; Dermatologic Agents; Drug Therapy, Co | 2000 |
An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Chemo | 2000 |
An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Chemo | 2000 |
Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments.
Topics: Administration, Topical; Anti-Inflammatory Agents; Clobetasol; Dermatologic Agents; Double-Blind Met | 2001 |
Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments.
Topics: Administration, Topical; Anti-Inflammatory Agents; Clobetasol; Dermatologic Agents; Double-Blind Met | 2001 |
Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Dermatologic Agents; Drug Eruptions; Drug Therapy, Combinatio | 2001 |
Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Dermatologic Agents; Drug Eruptions; Drug Therapy, Combinatio | 2001 |
Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study.
Topics: Adult; Dermatologic Agents; Double-Blind Method; Drug Evaluation; Female; Fingers; Gels; Humans; Mal | 2001 |
Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study.
Topics: Adult; Dermatologic Agents; Double-Blind Method; Drug Evaluation; Female; Fingers; Gels; Humans; Mal | 2001 |
Instrumental evaluation of retinoid-induced skin irritation.
Topics: Administration, Cutaneous; Adult; Calcitriol; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2002 |
Instrumental evaluation of retinoid-induced skin irritation.
Topics: Administration, Cutaneous; Adult; Calcitriol; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2002 |
Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Arm; Calcitriol; Clobetasol; Dermatologic Agent | 2002 |
Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Arm; Calcitriol; Clobetasol; Dermatologic Agent | 2002 |
47 other studies available for tazarotene and Psoriasis
| Article | Year |
|---|---|
An Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis.
Topics: Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Humans; Nicotinic Acids; Pi | 2021 |
An Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis.
Topics: Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Humans; Nicotinic Acids; Pi | 2021 |
Fixed Combination Halobetasol Propionate and Tazarotene Lotion for Plaque Psoriasis.
Topics: Administration, Cutaneous; Adult; Clobetasol; Dermatologic Agents; Drug Combinations; Humans; Nicoti | 2021 |
Fixed Combination Halobetasol Propionate and Tazarotene Lotion for Plaque Psoriasis.
Topics: Administration, Cutaneous; Adult; Clobetasol; Dermatologic Agents; Drug Combinations; Humans; Nicoti | 2021 |
Adjunctive Use of Halobetasol Propionate-Tazarotene in Biologic-Experienced Patients With Psoriasis.
Topics: Administration, Cutaneous; Adult; Biological Products; Clobetasol; Dermatologic Agents; Drug Combina | 2022 |
Adjunctive Use of Halobetasol Propionate-Tazarotene in Biologic-Experienced Patients With Psoriasis.
Topics: Administration, Cutaneous; Adult; Biological Products; Clobetasol; Dermatologic Agents; Drug Combina | 2022 |
Supplement Individual Article: A Reappraisal of Fixed-Combination Halobetasol Propionate and Tazarotene for the Treatment of Psoriasis: Biological Underpinnings, Therapeutic Mechanisms, and Economic Considerations.
Topics: Administration, Cutaneous; Dermatologic Agents; Drug Combinations; Emollients; Emulsions; Endothelia | 2023 |
Supplement Individual Article: A Reappraisal of Fixed-Combination Halobetasol Propionate and Tazarotene for the Treatment of Psoriasis: Biological Underpinnings, Therapeutic Mechanisms, and Economic Considerations.
Topics: Administration, Cutaneous; Dermatologic Agents; Drug Combinations; Emollients; Emulsions; Endothelia | 2023 |
An Investigator-Initiated Trial of a Polymeric Emulsion of Halobetasol Propionate and Tazarotene in the Treatment of Palmoplantar Psoriasis.
Topics: Adult; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Emulsions; Humans; N | 2023 |
An Investigator-Initiated Trial of a Polymeric Emulsion of Halobetasol Propionate and Tazarotene in the Treatment of Palmoplantar Psoriasis.
Topics: Adult; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Emulsions; Humans; N | 2023 |
Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology.
Topics: Clobetasol; Dermatologic Agents; Drug Combinations; Emulsions; Humans; Nicotinic Acids; Psoriasis; S | 2021 |
Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology.
Topics: Clobetasol; Dermatologic Agents; Drug Combinations; Emulsions; Humans; Nicotinic Acids; Psoriasis; S | 2021 |
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
Topics: Adolescent; Adrenal Cortex Hormones; Anthralin; Biological Products; Calcineurin Inhibitors; Cardiov | 2020 |
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
Topics: Adolescent; Adrenal Cortex Hormones; Anthralin; Biological Products; Calcineurin Inhibitors; Cardiov | 2020 |
Tazarotene-loaded
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Biocompatible Materials; Cell Line; Dermatologic Agen | 2020 |
Tazarotene-loaded
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Biocompatible Materials; Cell Line; Dermatologic Agen | 2020 |
Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion: Case Report
Topics: Administration, Cutaneous; Black or African American; Clobetasol; Drug Combinations; Esthetics; Huma | 2020 |
Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion: Case Report
Topics: Administration, Cutaneous; Black or African American; Clobetasol; Drug Combinations; Esthetics; Huma | 2020 |
Reply: Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matchi
Topics: Betamethasone; Calcitriol; Clobetasol; Humans; Nicotinic Acids; Psoriasis | 2020 |
Reply: Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matchi
Topics: Betamethasone; Calcitriol; Clobetasol; Humans; Nicotinic Acids; Psoriasis | 2020 |
Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adju
Topics: Betamethasone; Calcitriol; Clobetasol; Humans; Nicotinic Acids; Psoriasis | 2020 |
Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adju
Topics: Betamethasone; Calcitriol; Clobetasol; Humans; Nicotinic Acids; Psoriasis | 2020 |
Tazarotene/Betamethasone Dipropionate Cream in Patients with Plaque Psoriasis: Results of a Prospective, Multicenter, Observational Study.
Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Betamethasone; Dermatologic Agents; Drug | 2021 |
Tazarotene/Betamethasone Dipropionate Cream in Patients with Plaque Psoriasis: Results of a Prospective, Multicenter, Observational Study.
Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Betamethasone; Dermatologic Agents; Drug | 2021 |
Combination of retinoids and narrow-band ultraviolet B inhibits matrix metalloproteinase 13 expression in HaCaT keratinocytes and a mouse model of psoriasis.
Topics: Animals; Cell Line; Cell Proliferation; Disease Models, Animal; HaCaT Cells; Humans; Imiquimod; Kera | 2021 |
Combination of retinoids and narrow-band ultraviolet B inhibits matrix metalloproteinase 13 expression in HaCaT keratinocytes and a mouse model of psoriasis.
Topics: Animals; Cell Line; Cell Proliferation; Disease Models, Animal; HaCaT Cells; Humans; Imiquimod; Kera | 2021 |
Performance evaluation of non-ionic surfactant based tazarotene encapsulated proniosomal gel for the treatment of psoriasis.
Topics: Administration, Cutaneous; Animals; Male; Mice; Nicotinic Acids; Psoriasis; Rats; Surface-Active Age | 2017 |
Performance evaluation of non-ionic surfactant based tazarotene encapsulated proniosomal gel for the treatment of psoriasis.
Topics: Administration, Cutaneous; Animals; Male; Mice; Nicotinic Acids; Psoriasis; Rats; Surface-Active Age | 2017 |
Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis
Topics: Administration, Cutaneous; Clinical Trials, Phase III as Topic; Clobetasol; Dermatologic Agents; Dru | 2019 |
Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis
Topics: Administration, Cutaneous; Clinical Trials, Phase III as Topic; Clobetasol; Dermatologic Agents; Dru | 2019 |
Understanding topical therapies for psoriasis.
Topics: Administration, Cutaneous; Biological Products; Calcitriol; Dermatologic Agents; Drug Combinations; | 2019 |
Understanding topical therapies for psoriasis.
Topics: Administration, Cutaneous; Biological Products; Calcitriol; Dermatologic Agents; Drug Combinations; | 2019 |
A novel halobetasol propionate 0.01%/tazarotene 0.045% fixed combination treatment for psoriasis.
Topics: Administration, Cutaneous; Clobetasol; Dermatologic Agents; Drug Combinations; Humans; Nicotinic Aci | 2019 |
A novel halobetasol propionate 0.01%/tazarotene 0.045% fixed combination treatment for psoriasis.
Topics: Administration, Cutaneous; Clobetasol; Dermatologic Agents; Drug Combinations; Humans; Nicotinic Aci | 2019 |
Improving outcomes in patients with psoriasis.
Topics: Adrenal Cortex Hormones; Anthralin; Calcineurin Inhibitors; Calcitriol; Dermatologic Agents; Humans; | 2013 |
Improving outcomes in patients with psoriasis.
Topics: Adrenal Cortex Hormones; Anthralin; Calcineurin Inhibitors; Calcitriol; Dermatologic Agents; Humans; | 2013 |
The only topical retinoid without a generic alternative: tazarotene.
Topics: Acne Vulgaris; Dermatologic Agents; Drug Approval; Drugs, Generic; Humans; Nicotinic Acids; Psoriasi | 2013 |
The only topical retinoid without a generic alternative: tazarotene.
Topics: Acne Vulgaris; Dermatologic Agents; Drug Approval; Drugs, Generic; Humans; Nicotinic Acids; Psoriasi | 2013 |
Köebner phenomenon induced by cupping therapy in a psoriasis patient.
Topics: Adult; Clarithromycin; Clobetasol; Ecchymosis; Humans; Male; Medicine, Chinese Traditional; Nicotini | 2013 |
Köebner phenomenon induced by cupping therapy in a psoriasis patient.
Topics: Adult; Clarithromycin; Clobetasol; Ecchymosis; Humans; Male; Medicine, Chinese Traditional; Nicotini | 2013 |
A comparison of the effects of topical treatment of calcipotriol, camptothecin, clobetasol and tazarotene on an imiquimod-induced psoriasis-like mouse model.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Animals; Anti-Inflammatory Agents; | 2014 |
A comparison of the effects of topical treatment of calcipotriol, camptothecin, clobetasol and tazarotene on an imiquimod-induced psoriasis-like mouse model.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Animals; Anti-Inflammatory Agents; | 2014 |
Periungual pyogenic granulomas due to topical tazarotene for nail psoriasis.
Topics: Administration, Cutaneous; Adult; Aged; Dermatologic Agents; Female; Granuloma, Pyogenic; Humans; Ma | 2014 |
Periungual pyogenic granulomas due to topical tazarotene for nail psoriasis.
Topics: Administration, Cutaneous; Adult; Aged; Dermatologic Agents; Female; Granuloma, Pyogenic; Humans; Ma | 2014 |
Phospholipid membrane tubulation using ceramide doping "Cerosomes": Characterization and clinical application in psoriasis treatment.
Topics: Administration, Cutaneous; Ceramides; Chemistry, Pharmaceutical; Dermatologic Agents; Drug Carriers; | 2017 |
Phospholipid membrane tubulation using ceramide doping "Cerosomes": Characterization and clinical application in psoriasis treatment.
Topics: Administration, Cutaneous; Ceramides; Chemistry, Pharmaceutical; Dermatologic Agents; Drug Carriers; | 2017 |
Childhood psoriasis: often favorable outcome.
Topics: Acitretin; Administration, Topical; Anthralin; Calcitriol; Child; Cyclosporine; Dermatologic Agents; | 2009 |
Childhood psoriasis: often favorable outcome.
Topics: Acitretin; Administration, Topical; Anthralin; Calcitriol; Child; Cyclosporine; Dermatologic Agents; | 2009 |
Topical treatments for chronic plaque psoriasis.
Topics: Disease Progression; Female; Glucocorticoids; Humans; Middle Aged; Nicotinic Acids; Psoriasis; Retin | 2010 |
Topical treatments for chronic plaque psoriasis.
Topics: Disease Progression; Female; Glucocorticoids; Humans; Middle Aged; Nicotinic Acids; Psoriasis; Retin | 2010 |
Evaluation of the antipsoriatic activity of Aloe vera leaf extract using a mouse tail model of psoriasis.
Topics: Aloe; Animals; Cell Differentiation; Dermatologic Agents; Disease Models, Animal; Drug Evaluation, P | 2012 |
Evaluation of the antipsoriatic activity of Aloe vera leaf extract using a mouse tail model of psoriasis.
Topics: Aloe; Animals; Cell Differentiation; Dermatologic Agents; Disease Models, Animal; Drug Evaluation, P | 2012 |
Nail psoriasis: treatment with tazarotene 0.1% hydrophilic ointment.
Topics: Dermatologic Agents; Humans; Nail Diseases; Nicotinic Acids; Ointments; Psoriasis | 2012 |
Nail psoriasis: treatment with tazarotene 0.1% hydrophilic ointment.
Topics: Dermatologic Agents; Humans; Nail Diseases; Nicotinic Acids; Ointments; Psoriasis | 2012 |
Short-contact therapy with tazarotene in psoriasis vulgaris.
Topics: Administration, Topical; Adult; Aged; Dermatologic Agents; Female; Humans; Male; Middle Aged; Nicoti | 2003 |
Short-contact therapy with tazarotene in psoriasis vulgaris.
Topics: Administration, Topical; Adult; Aged; Dermatologic Agents; Female; Humans; Male; Middle Aged; Nicoti | 2003 |
Investigational therapies for psoriasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Daclizumab; Dermatologic Agents; Drugs, I | 2003 |
Investigational therapies for psoriasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Daclizumab; Dermatologic Agents; Drugs, I | 2003 |
Modern modified 'ultra' Goeckerman therapy: a PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies.
Topics: Acitretin; Anthralin; Calcitriol; Coal Tar; Combined Modality Therapy; Female; Humans; Keratolytic A | 2005 |
Modern modified 'ultra' Goeckerman therapy: a PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies.
Topics: Acitretin; Anthralin; Calcitriol; Coal Tar; Combined Modality Therapy; Female; Humans; Keratolytic A | 2005 |
Chronically painful right thumb with pustules and onycholysis. Diagnosis: acrodermatitis continua of Hallopeau.
Topics: Acrodermatitis; Aged; Chronic Disease; Dermatologic Agents; Diagnosis, Differential; Female; Humans; | 2007 |
Chronically painful right thumb with pustules and onycholysis. Diagnosis: acrodermatitis continua of Hallopeau.
Topics: Acrodermatitis; Aged; Chronic Disease; Dermatologic Agents; Diagnosis, Differential; Female; Humans; | 2007 |
Effects of topically applied acitretin in reconstructed human epidermis and the rhino mouse.
Topics: Acitretin; Administration, Topical; Animals; Disease Models, Animal; Epidermis; Female; Filaggrin Pr | 2008 |
Effects of topically applied acitretin in reconstructed human epidermis and the rhino mouse.
Topics: Acitretin; Administration, Topical; Animals; Disease Models, Animal; Epidermis; Female; Filaggrin Pr | 2008 |
Tazarotene-induced irritation causing vitiligo by Koebnerization.
Topics: Dermatologic Agents; Humans; Male; Middle Aged; Nicotinic Acids; Psoriasis; Vitiligo | 2007 |
Tazarotene-induced irritation causing vitiligo by Koebnerization.
Topics: Dermatologic Agents; Humans; Male; Middle Aged; Nicotinic Acids; Psoriasis; Vitiligo | 2007 |
Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin.
Topics: Amino Acid Sequence; Base Sequence; Biopsy; Culture Techniques; Gene Expression; Humans; In Situ Hyb | 1996 |
Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin.
Topics: Amino Acid Sequence; Base Sequence; Biopsy; Culture Techniques; Gene Expression; Humans; In Situ Hyb | 1996 |
Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acid receptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis.
Topics: Antigens, Differentiation; Antineoplastic Agents; Biomarkers; Calcium-Binding Proteins; Calgranulin | 1996 |
Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acid receptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis.
Topics: Antigens, Differentiation; Antineoplastic Agents; Biomarkers; Calcium-Binding Proteins; Calgranulin | 1996 |
Early clinical development of tazarotene.
Topics: Clinical Trials as Topic; Gels; Humans; Nicotinic Acids; Psoriasis; Randomized Controlled Trials as | 1996 |
Early clinical development of tazarotene.
Topics: Clinical Trials as Topic; Gels; Humans; Nicotinic Acids; Psoriasis; Randomized Controlled Trials as | 1996 |
Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin.
Topics: Administration, Topical; Amino Acid Sequence; Base Sequence; Calcitriol; Cells, Cultured; Chromosome | 1997 |
Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin.
Topics: Administration, Topical; Amino Acid Sequence; Base Sequence; Calcitriol; Cells, Cultured; Chromosome | 1997 |
Topical retinoid introduced for plaque psoriasis, acne vulgaris.
Topics: Acne Vulgaris; Dermatologic Agents; Humans; Nicotinic Acids; Prodrugs; Psoriasis; Retinoids | 1997 |
Topical retinoid introduced for plaque psoriasis, acne vulgaris.
Topics: Acne Vulgaris; Dermatologic Agents; Humans; Nicotinic Acids; Prodrugs; Psoriasis; Retinoids | 1997 |
Two new retinoids for psoriasis.
Topics: Abnormalities, Drug-Induced; Acitretin; Alopecia; Cheilitis; Clinical Trials as Topic; Dermatologic | 1997 |
Two new retinoids for psoriasis.
Topics: Abnormalities, Drug-Induced; Acitretin; Alopecia; Cheilitis; Clinical Trials as Topic; Dermatologic | 1997 |
New treatment options for psoriasis.
Topics: Administration, Topical; Anti-Inflammatory Agents; Dermatologic Agents; Humans; Nicotinic Acids; Pat | 1997 |
New treatment options for psoriasis.
Topics: Administration, Topical; Anti-Inflammatory Agents; Dermatologic Agents; Humans; Nicotinic Acids; Pat | 1997 |
Genital ulcers in a psoriasis patient using topical tazarotene.
Topics: Drug Eruptions; Genital Diseases, Male; Humans; Keratolytic Agents; Male; Middle Aged; Nicotinic Aci | 1998 |
Genital ulcers in a psoriasis patient using topical tazarotene.
Topics: Drug Eruptions; Genital Diseases, Male; Humans; Keratolytic Agents; Male; Middle Aged; Nicotinic Aci | 1998 |
New horizons in the management of psoriasis: introduction.
Topics: Clinical Trials as Topic; Dermatologic Agents; Humans; Nicotinic Acids; Psoriasis; Treatment Outcome | 1998 |
New horizons in the management of psoriasis: introduction.
Topics: Clinical Trials as Topic; Dermatologic Agents; Humans; Nicotinic Acids; Psoriasis; Treatment Outcome | 1998 |
Excerpt of panel discussion from symposium.
Topics: Administration, Topical; Clinical Trials as Topic; Dermatologic Agents; Female; Humans; Nicotinic Ac | 1998 |
Excerpt of panel discussion from symposium.
Topics: Administration, Topical; Clinical Trials as Topic; Dermatologic Agents; Female; Humans; Nicotinic Ac | 1998 |
Obtaining the optimal treatment outcome with tazarotene.
Topics: Dermatologic Agents; Gels; Humans; Nicotinic Acids; Patient Education as Topic; Psoriasis; Retinoids | 1998 |
Obtaining the optimal treatment outcome with tazarotene.
Topics: Dermatologic Agents; Gels; Humans; Nicotinic Acids; Patient Education as Topic; Psoriasis; Retinoids | 1998 |
Optimising the use of tazarotene in clinical practice: consensus statement from the European advisory panel for tazarotene (Zorac TM).
Topics: Humans; Keratolytic Agents; Nicotinic Acids; Practice Guidelines as Topic; Psoriasis | 1999 |
Optimising the use of tazarotene in clinical practice: consensus statement from the European advisory panel for tazarotene (Zorac TM).
Topics: Humans; Keratolytic Agents; Nicotinic Acids; Practice Guidelines as Topic; Psoriasis | 1999 |
In vitro compatibility of tazarotene with other topical treatments of psoriasis.
Topics: Administration, Topical; Betamethasone; Calcitriol; Clobetasol; Dermatologic Agents; Drug Evaluation | 2000 |
In vitro compatibility of tazarotene with other topical treatments of psoriasis.
Topics: Administration, Topical; Betamethasone; Calcitriol; Clobetasol; Dermatologic Agents; Drug Evaluation | 2000 |
Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis.
Topics: Angiopoietin-1; Angiopoietin-2; Cytokines; Dermatologic Agents; Endothelium, Vascular; Humans; Membr | 2001 |
Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis.
Topics: Angiopoietin-1; Angiopoietin-2; Cytokines; Dermatologic Agents; Endothelium, Vascular; Humans; Membr | 2001 |